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Chapter
General introduction

GENERAL iNTRODUCTiO N 1
C erebral pa lsy (CP) is the m ost frequent cause of physica l d isab ility  in children 
and can be defined as a d isorder of aberrant contro l of m ovem ent and posture, 
appearing  early in life (before the first birthday) secondary  to a non progressive 
CNS lesion. The w orldw ide  prevalence of CP is approx im ate ly  2 to 2.5 per 1000 
live b irths.1 C om m on add itiona l im pairm ents are sensory dysfunction  (seeing, 
hearing), cogn itive  and behaviora l de fic its, and dysfunctiona l oral m otor contro l 
ham pering  the ab ility  of a ch ild  to realize his or her in trinsic deve lopm enta l 
potential. A lthough not precisely established, one out of three individuals with CP 
drools to some extent. Drooling contributes heavily to the burden in children with 
CP and social alienation they experience.2,3 During recent years there is increasing 
evidence that children who drool m ight benefit from behavioral m odifying therapy4 
or from  m ore invasive techn iques  like u ltrasound-gu ided  Botu linum  Toxin type  A 
in jec tions (BoNT-A) into the subm and ibu la r g la n d s5 or surgery.6 Research is now 
focused  on refin ing the droo ling  the rapy and on evaluation of the e fficacy  of the 
d iffe rent in terventions. An outline of these find ings  will prov ide the c lin ic ian  w ith 
essentia l in form ation on wh ich a rational trea tm ent stra tegy can be based.
Aims and Study design
The princ ipa l ob jective  of th is  thes is  is to refine u ltrasound-gu ided  subm and ibu la r 
BoNT-A in jection to treat d roo ling  and to provide basic concep ts  fo r the 
m echan ism s tha t underlie the droo ling  prob lem . Therefore, a prospective  cohort 
s tudy was perfo rm ed in 151 Dutch ch ildren w ith e ither CP or w ith exclusive ly 
‘ in te llectua l d is a b ility ’.
A ll participants  were screened in the ou tpa tien t d roo ling  c lin ic  at the Radboud 
U n iversity N ijm egen M edica l Centre, The N etherlands between February 2000 
and M arch 2010.
Inclusion  criteria: ch ildren aged 3 -19  years (male and female); con firm ed 
d iagnos is  of cerebra l pa lsy or exclusive ly m ental d isab ility  (m edical history, 
neuro log ica l exam ination, m agnetic  resonance im aging (MRI), e lec troe ncep ha lo ­
graphy); score of > 3 on droo ling  severity and frequency sca le7 (ind ica ting 
m odera te to profuse drooling); in form ed consen t from  parents /ca reg ivers. 
Exclusion criteria: p rogressive neuro log ica l cond ition ; enro lm ent in another 
m edica l study; previous surg ica l p rocedure  for saliva contro l; use of d rugs that
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in terfere w ith saliva secre tion (an ticho linerg ic  and neuro lep tic  drugs, benzo­
diazepines).
The mean age of the ch ildren was 10 years/ten  m onths w ith a S tandard Deviation 
(SD) of 4 yea rs /10 m onths. M ost of the ch ildren w ith CP were non-am bu la to ry  and 
70% of them  had an Inte lligence Q uotien t (IQ) be low  70. All ch ildren w ith 
in te llectua l d isab ilities  were am bulatory, and also had an IQ be low  70. 
Procedures. An u ltrasound-gu ided  in jection of BoNT-A was given b ilaterally into 
the subm and ibu la r salivary g lands. A to ta l dose of up to 50 U Botox® (A llergan
B.V., N ieuw egein, The Netherlands) was used.
Scoring. Both, d roo ling  in tensity and salivary flow  were m easured at baseline, 
8 weeks and 32 weeks after in jection. D rooling in tensity was evaluated using the 
droo ling  quotien t (DQ), a sem i quan tita tive  observa tiona l m ethod (expressed as 
a percentage). The DQ was scored acco rd ing  to the orig ina l design  by recording 
all ep isodes of drooling during 10 minutes, while watching TV. A drooling episode 
was defined as new saliva be ing present on the lip m argin or d ripp ing  from  
the chin. The presence or absence of d roo ling  was assessed every 15 seconds 
(40 observa tions in 10 m inutes).8
To m easure the sa livary flow  rate the swab test is used: after dry ing  the oral cavity 
w ith  sterile gauze, three absorben t denta l co tton  rolls (Salivette®; Sarstedt B.V., 
Etten-Leur, The Netherlands) were p laced in the oral cav ity  fo r a 5 m inute-period: 
be low  the tongue in front of the orifices of the subm and ibu la r and sub lingual 
g lands as well as in the upper vestibu les at the open ings of the parotid  ducts. The 
roll under the tongue and the tw o upper vestibu les-ro lls  were w e igh ted separa te ly 
to be de fined as subm and ibu la r and parotid  flow. The increase in w e igh t during 
the 5-m inute period was converted into m illiliters of saliva per m inute to de term ine 
sa livary flow  rate.9
Primary Outcome Measures: Success to the rapy was de fined as a 30% 
subm and ibu la r flow  reduction  and /o r a 50% reduction  in DQ com pared  to 
baseline. The 30% dem and has been previously reported and is exp la ined by the 
estim ated m easurem ent error of the swab m ethod to evaluate the sa livary flow  
rate.9
Earlier it has been successfu lly  stated tha t a 50% reduction  in the Drooling 
Q uotient reflects a c lin ica l relevant change.5 The subm and ibu la r g lands, in fact 
the com b ined  saliva of the subm and ibu la r and sub lingua l g lands, p roduce about 
60 to 70% of baseline sa livary flow  in the situa tion a person does not eat or drink.
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In the event the D rooling Q uotient is reduced by 50% fo llow ing Botu linum  Toxin 
in jec tions the change of flow  from  the subm and ibu la r g lands, be ing the only 
g land exposed to th is  in tervention, m ust have added substantia lly  to th is 
reduction. A care taker v isual analog scale (VAS) score reflecting the severity of 
drooling over the previous 2 weeks served as secondary outcom e measure. After 
rece iv ing spec ific  instructions, care takers were asked to m ark the extent of 
d roo ling  on a 10-cm  line. The VAS score was ob ta ined by m easuring the position 
of the m ark in m illim eters from  the left end of the scale on a scale ranging from  0 
to 100, the latter representing severe drooling . A change of 2 SD reduction 
com pared  to the baseline VAS score was cons idered  c lin ica lly  s ign ifican t.10
Outline of this thesis
This thesis is d iv ided into three sections. The first section, chapter 2, gives an 
overview  how dysfunctiona l neuronal ne tw orks of sw a llow ing con tribu te  to a 
neglected clin ica l problem : the basic concep ts  of droo ling . The im paired cerebra l 
neuronal ne tw ork in cerebra l pa lsy is presented as a c lin ica l m odel to illustrate a 
com prehensive  fram ew ork considera te  as crucia l to coo rd ina te  oral sensorim o to r 
func tions  along w ith associa ted upper and lower gastro in testina l functions. The 
de le te rious c lin ica l consequences  of d is tu rbances  of th is concep tua l fram ew ork 
are d iscussed. Generally, it has been accep ted  tha t dysfunctiona l oral m otor 
function  plays a centra l role in droo ling . Chapter 3 presents a c a s e -c o n tro l study 
to de term ine w hether excessive saliva p roduc tion  in droo ling  ch ildren d iagnosed 
w ith  CP exists and m ight be a cofactor. We also hypothesize tha t saliva secre tion 
in ch ildren w ith dysk ine tic  CP m ight be increased because of the added 
m echan ica l stim ulation of the salivary g lands as a result of hyperk ine tic  oral 
m ovem ents.
In the second section, we present the re-evaluation of the e fficacy  of BoNT-A 
the rapy for droo ling . A fte r the firs t report on BoNT-A as being an alternative, 
m in im ally invasive trea tm ent for drooling , several stud ies have been pub lished on 
this treatment. As we have been treating children in our m ultid isciplinary outpatient 
d roo ling  c lin ic  s ince 1999 we have build up a large experience on th is  sub ject. As 
the effectiveness be ing dem onstra ted, we becam e m ore interested in the e fficacy 
and duration of the e ffect of BoNT-A w hen used on a large scale in c lin ica l
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practice. We report abou t our experience after treating 131 ch ildren w ith 
subm and ibu la r BoNT-A in chapter 4. Earlier d roo ling  trea tm ent results showed 
tha t up to 30 % of pa tien ts d id  not respond to subm and ibu la r in jection of BoNT-A 
if response was de fined as a 30% reduction  of subm and ibu la r sa livary flow  in 
com b ina tion  w ith a 50% reduction  of the D rooling Q uotien t (DQ).511 Given the 
num ber of non-responders, fu rthe r research necessita tes to search fo r factors 
tha t cause the rapy failure. Currently, there is no agreem ent abou t w hat ch ild  char­
acte ris tics  will d is tingu ish  between a “succe ss fu l” or “ un succe ss fu l” the rapy 
response after subm and ibu la r BoNT-A in jections. A fte r com p le ting  a tho rough  
literature study, we iden tified tha t the fo llow ing fac to rs  are suggested to con tribu te  
to droo ling  severity: head position, lip seal, vo lun ta ry  contro l of tongue  m ovem ents, 
contro l of vo lun ta ry  m ovem ent functions, and m ental age. In chapter 5 we explore 
w hethe r m otor pe rfo rm ance con tribu tes to the rapy outcom e, and chapter 6 
describes  the first a ttem pt to reveal the con tribu tion  of head position, tongue 
pro trusion, lip seal, vo lun ta ry  tongue contro l, deve lopm enta l age, contro l of 
vo lun ta ry  m ovem ents, dysa rth ria  and dysphag ia  (as defined by the International 
C lass ifica tion  of Functioning, D isab ility  and Health for Children and Youth 
(ICF-CY)) to the ou tcom e of subm and ibu la r BoNT-A for drooling . M eanwhile, we 
observed in som e ch ildren salivary th icken ing and increased feeding, speech 
and sw allow ing prob lem s after subm and ibu la r BoNT-A. In view  of the an ticho lin ­
erg ic  prope rties  of BoNT, it is likely tha t the w atery com ponen t of saliva will be 
reduced and that the sa livary v isco s ity  will increase post-BoNT. Therefore, we 
assum ed tha t the s ticky  saliva m ight cause the sw allow ing prob lem s due to 
increased prote in concen tra tions and changed sa livary v isco s ity  causing more 
fric tion .12 In C hapter 7 we report on th is  experience and describe  the increased 
risk of sw allow ing prob lem s due to th icken ing of saliva after e ffective m anagem ent 
w ith  subm and ibu la r BoNT-A in jections.
The im portance  to estab lish the im pact of d roo ling  and its trea tm ent on health 
and qua lity  of live is s tressed in the last section. G iven the costs  of BoNT-A and 
the fact tha t BoNT has to be repeatedly applied , w h ile need ing aesthesia in 
children, it is im portan t to form ulate stric t ind ica tions fo r th is  therapy. C hapter 8 
reports  on an in ternational Botu linum  Toxin Therapy consensus sta tem ent for 
drooling , and hope fu lly  assists the c lin ic ians w ith the assessm ent, in tervention 
and m anagem ent of ch ildren and adu lts  w ith drooling . C hapter 9 sum m arises the 
m ain find in gs  of th is thes is  and presents suggestions for fu ture c lin ica l research.
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CHAPTER 2
Abstract
Defective sw allow ing and subsequent excessive droo ling  are substantia l 
p rob lem s in a large num ber of neuro log ica lly  a ffected indiv iduals. As trea tm ent of 
the underly ing d iso rder often lacks, trea tm ent of sym ptom s to m aintain qua lity  of 
life is worthwhile. The current review focuses on disturbed regulation of swallow ing 
tha t leads to dysphag ia  and drooling , and in tegrates the accum ula ting  evidence 
abou t functiona l and spatia l d is tinc t brain reg ions involved in sw allow ing. Cerebral 
Palsy is used as a clinical model to illustrate the com prehensive fram ework crucial 
for coo rd ina ting  oral m otor and associa ted gastro in testina l functions, and to 
d iscuss the deleterious c lin ical consequences of d is tu rbances of th is fram ework. 
A t an early stage, pa rticu la r note should be m ade to the im portan t con tribu tion  of 
dysphag ia  and droo ling  to the burden of the ch ild  and h is/her family. The 
form ulation of rational prognostic  statem ents of dysphagia is based on awareness 
of the top o g ra p h ic  brain injury.
20
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Search strategy and selection criteria
M em bers of the M u ltid isc ip lina ry  O utpa tien t D rooling C lin ic at the Radboud 
University Nijmegen Medical Centre in The Netherlands continually review literature 
on dysphagia and drooling in neurologically affected patients. References for th is 
review were ob ta ined from  personal reprint files, supp lem en ted  by Pub Med 
searches, w ith vary ing  search pe riods (from 2005 to February 2011). The search 
term s “droo ling ”, “saliva”, “sia lorrhea”, “swa llow ing”, “dysphag ia”, “cerebral pa lsy”, 
“ch ild re n ”, “ brain reg io ns ”, “au to n o m ic ”, “ fM R I”, and “ th e ra p y ” were used. Only 
English language artic les were included. The final reference list was generated 
based on o rig ina lity  and relevance to the to p ics  covered in the review.
Neural control of swallowing
Norm al sw a llow ing is a goa l-d irec ted  sequentia l behaviour tha t requires the 
coo rd ina ted  action and inh ib ition of the m uscles located b ilaterally around the 
o ropharynx and oesophagus. The sw allow ing p rocess is con tro lled  in a com plex 
m anner involving the bra instem  as well as cortica l and subco rtica l centra l 
pathways. In addition, it requires a h igher level of fine -tun ing  between the centra l 
c ircu its  and the enteric nervous system s (ENS).
A ccurate swallow ing is dependent on sensory input from  the oropharynx triggering 
bilateral afferents in specific  regions of the trigem inal sensory nuclei. Subsequently, 
the inputs reach the brainstem  regions responsib le for the patterned m otor actions 
of swallow ing. It is by now established, that the sequentia l and rhythm ic patterns of 
swallow ing are form ed and organized by a central pattern generator (CPG) located 
in the m edulla ob longata. The CPG consists of two hem i-CPG s which, under 
physio log ica l conditions, are tigh tly  synchronized. The swallow ing m otor sequence 
is m ainly generated in the ipsi-lateral hem i-CPG w hich transfers the prem otor 
neuron signals to the contra-lateral CPG.1 The CPG itself is organized into two 
groups of neurons: the dorsal swallow ing group (DSG) in and around the nucleus 
of tractus solitarius (NTS) and the ventral swallow ing group (VSG) just cranial to the 
am b iguus nucleus (NA). The DSG contains the generator neurons involved in the 
triggering, shaping and tim ing of the sequentia l or rhythm ic swallow ing pattern. The 
DSG activates all VSD prem otor neurons w h ich in turn d istribu te the swallow ing
21
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drive to the various m otor neuron pools involved in swallowing. The m ultifunctional 
pattern generating c ircu its of the brainstem  allow  rapid m odulation of orofacial 
behaviours (swallowing, respiration, chewing, cough ing and vom iting ).2 A lthough 
our know ledge of the cortica l regions involved in swallow ing has grown substantia lly 
trough functional m agnetic resonance im aging (fMRI) studies, the exact central 
contro l for swallow ing is still not fully understood. The involvem ent of many 
functiona lly  and spatia lly  different cortica l sites suggests multilevel contro l for the 
swallow ing pathways. It has been proposed that the contro l system consists of 
parallel loops which are able to coordinate and integrate the com plex sequentia lly 
based activation for sw a llow ing.3 The prim ary m otor area, c ingulated and insular 
cortices m ight all have essential roles in the coord ination of the entire swallow ing 
process.4-6 Some investigators assume a functional dom inance in swallow ing1,7 or a 
tim e-dependen t shift of cortica l activation from  the left to right sensorim otor cortex 
during volitional sw allow ing.8
In sum m ary, vo lun ta rily  and reflexive sw allow ing is con tro lled  by w ide ly  d is tribu ted 
bilateral and m ultifoca l co rtica l ne tw orks w ith apparen tly  ove rlapp ing cortica l 
regions. The p rim ary sensory, motor, and c ingu la ted co rtices  have a m ajor role in 
these networks. The execution of the sensorim o to r aspects  related to swallow ing 
rely on functiona lly  connected pathways between (extra)pyram idal cortica l m otor 
p lanning regions, centres con tro lling  the bra instem  and crania l nerves as well as 
lower m otor neurons.
Norm al gastro in testina l trac t (GI) function  results from  a ba lanced in teraction 
between the enteric nervous system  (ENS) and the centra l nervous system  (CNS) 
w h ich  is ca lled “the b ra in -gu t ax is ”. The ENS neuronal as well as horm onal 
com m un ica tions  have im portan t in tegrative functions. A deta iled d iscuss ion  of 
the horm onal pathways is beyond of the scope  of th is  artic le. The ENS neural 
com m un ica tions  cons is t of the in trinsic a fferent and m otor neurons d is tribu ted 
a long the m esenteric A uerbach and subm ucosa l M eissner plexus, located in the 
w a lls  of the gut. The afferent (vagal) sensory fib res term inate in the NTS of the 
h indbrain. The p regang lion ic  m otor innervations to the plexus arise from  the 
dorsa l m otor nucleus of the vagus in the brainstem . The NTS and the vagal dorsal 
m otor nucleus toge the r com prise  the dorsa l vagal com plex, im portan t in the 
coo rd ina tion  of the m uscu lar ac tiv ity  of the gu t (vago-vagal reflex).9 The 
oesophagus consists of a proxim al striated m uscle portion (upper oesophageal 
sphincter, UOS) and a d ista l sm ooth  m uscle po rtion  (lower oesophagea l
22
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sphincter, LOS). At rest both sph incte rs  are ton ica lly  con tracted. Relaxation of the 
UOS (g lossopharyngea l and vagal nerves) is in itiated in the sw allow ing centre 
located in the m edulla. Relaxation and contraction of the LOS (vagal and sp lanchic 
nerves) are in itiated th rough local pe ris ta ltic  ac tiv ity  of the oesophagus or 
d is tension of the gastric  wall. Thus far the exact coup ling  of d is tinc t in terneurons 
in the NTS is not known. Also, it is not to ta lly  c lear w h ich  cortica l reg ions are 
m ainly involved in process ing  in form ation to the GI tract. It has been suggested 
tha t the anterio r insular cortex (called “v iscera l co rtex”), the prefrontal and 
sensory /m oto r regions, the c ingu la te  gyrus, as well as the lim b ic regions, all 
pa rtic ipa te  in the in tegra tion of neuronal in form ation to the GI trac t.10
Pathophysiology of dysphagia in cerebral palsy
D ysphag ia  is a sym ptom  that can be encountered in m any d iffe rent CNS d isorders 
as well as those of the periphera l nervous system  (PNS). We have chosen to use 
cerebra l pa lsy (CP) as a m odel to describe  the pa thophys io logy  of dysphag ia , as 
well as its d iagnos is  and the rapeu tic  in terventions.
CP is the m ost com m on physica l d isab ility  in early ch ildhood . It has been c lin ica lly  
defined as a group of motor, cognitive, and perceptive im pairm ents secondary to 
a non-progressive  defect or lesion of the deve lop ing  brain. Epilepsy is a com m on 
prob lem  in patien ts w ith CP. Seventy to 80% of CP cases arises from  antenatal 
factors and birth asphyxia  con tribu tes approx im ate ly  to 10% of the CP cases. 
A cqu ired  cases after the prenatal period are usually related to centra l nervous 
system  infection, traum a, strokes, and severe hypoxic events such as 
near-drowning. Genetic disorders and acquired insults follow a pattern of selective 
vu lne rab ility  during early brain developm ent. The neonatal neuropa tho log ica l 
corre la tes inc lude spec ific  and well known patterns of brain in jury (see Table 1). 
We th ink  tha t the unders tand ing  of dysphag ia  in the d iffe rent CP sub types  m ight 
be fac ilita ted by aw areness of the top og ra ph y  of the neuronal injury.
A recent ep idem io log ica l s tudy based on the analysis of ch ildren recorded by the 
Northern Ireland Cerebral Palsy Register (NICPR) between 1992 and 2009 
showed a high inc idence of dysphag ia  in any degree in ch ildren w ith CP.11 Results 
from  speech pa tho logy  testing and v id eo fluo ro scop ic  sw allow ing stud ies in CP 
ch ildren dem onstra te the re la tionship between typ ica lly  a ffected brain reg ions
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Table 1 Regions with a predilection for hypoxic-ischem ic neuronal injury
A. Periventricular leucomalacie (preterm  babies a n d  p ro lo n g e d  pa rtia l asphyxia)
B. Cortical and subcortical injury in a watershed parasagittal distribution (term bab ies  
a n d  p ro lo n g e d  m ilde r hypoxic events).
C. Injury in the thalami, basal ganglia, hippocampi, dorsal mesencephalic structures, 
perirolandic cortex (term bab ies an d  acu te anoxic events).
D. Diffuse, destructive anoxic-ischemic event resulting in widespread replacement 
of cerebral cortex and white matter by one or more cavities of variable sizes 
(multicystic encephalopathy).
and the associa ted cha racte ris tic  pa tte rns of dysfunctiona l sw allow ing. Usually, 
c lin ica l features such as delayed in itia tion and segm ented sw allow ing during 
a ttem pted  vo litiona l m ovem ent m ight be de term ined by cortica l neuronal 
networks, w h ile dysfunctiona l pharyngea l com ponents  of sw allow ing [i.e. 
au tom atic  com ponents  of deg lu tition , such as th roa t c learing, laryngeal closure 
tasks] suggest sub co rtica l brain in jury and basal gang lia  necrosis. In CP 
dysphagia is often characterized by problem s in both the volitional oral movements 
and the more reflective pharyngea l phase of sw allow ing. Moreover, im paired 
ab ility  to plan and coord ina te  sw allow ing w ith ven tila tion [e.g. greater p ropens ity  
to swallow at abnorm al tim es within the respiratory cycle, such as early inspiration 
after a th in liquid sw allow  and variab le  duration of the deg lu tition  apnoea] are 
cons is ten t w ith bra instem  involvem ent.12 A c lin ico -pa th o lo g ica l corre la tion 
between d iffe rences in b reath-sw allow  pattern and the risk for asp ira tion is likely. 
C linically, asp ira tion m anifests as frequently  cough ing , ep isod ic  asp ira tion, and 
occas iona l pneum onia. The overall inc idence  of pu lm onary  asp ira tion in CP due 
to oral m otor dysfunctions is not yet known precisely, but th is  inc idence m ust be 
high. Hospita lizations for respiratory reasons and presum ed aspiration pneum onia 
in ch ildren w ith CP are com m on. It has prev iously been found in a s tudy am ong 
238 children with recurrent pneum onia that 48% had oropharyngeal incoordination 
w ith  an asp ira tion  syndrom e, 50% of these ch ildren were d iagnosed  w ith CP 13. 
V id eo fluo ro scop ic  eva luation of dysphag ia  in CP has dem onstra ted pu lm onary  
asp ira tion in 38%14 to over 70% of the cases15 and frequently  the asp ira tion
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occu rred  “s ilen tly ” (w ithout cough ing ).1416 Chron ic pu lm onary  asp ira tion lead to 
chron ic cough ing , poss ib ly  s leep d isordered breathing, im paired c learance of 
a irway secre tions and co lon iza tion  by pa thogen ic  bacteria  of the airways, and 
there is a h igh -risk  of ongo ing  lung parenchym al dam age and death.17 
In add ition  to asp ira tion due to dysphag ia , chron ic  pu lm onary  asp ira tion in 
ch ildren w ith CP m ay also occu r as a result of the gastro  oesophagea l reflux 
(GOR)18. The inc idence of GOR has been estim ated at approx im ate ly  50%19 and 
m ight be exp la ined by lesions in the sw allow ing centre located in the m edulla 
ob longa ta  leading to dysfunction  of the vago-vaga l reflex. In add ition , GOR in 
children with CP may also result from direct lesions in cortical areas that m odulate 
bra instem  activ ity .920
C onstipa tion , a com m on dysm o tility  d iso rder of the gut in ch ildren w ith  CP, is 
often overlooked in th is  popu lation. More than half of the ch ildren w ith severe 
genera lized CP are con s tipa te d .21 The high inc idence of the dysm o tility  d isorders 
em phasizes the defective in tegra tion and m odu la tion  of in fo rm ation w ith in  the 
b ra in -gu t axis in CP, for w h ich  som e investigators had proposed the term  
“ D ysphagia -G O R  co m p le x ”, w ith a centra l role for the vagal nerve.22 It is 
reasonable to assum e tha t vagal d is rup tion  is responsib le  for de fective feedback  
to the d is tinc t co rtica l reg ions and bra instem  w h ich  are associa ted w ith swallow ing 
disorders, defective ventila tion as well as dysm otility  problem s. At this tim e more 
studies are needed to investigate the clinical relevance of integrated breathing, GI 
and swallowing function on the health and nutritional outcom es of children with CP. 
D rooling is caused by the sw allow ing d iso rder and occu rs  in 10% to 58% of 
ch ildren w ith CP.23-25 From a c lin ica l po in t of view  it m akes sense to d is tingu ish  
between “an te rio r” and “ posterio r d ro o lin g ”. A nterior d roo ling  is the un intentional 
loss of saliva from  the m outh. A nte rio r d roo ling  can im pose a s ign ifican t d isab ility  
on children w ith CP, leading to psycho-soc ia l, physica l and educa tiona l 
consequences. The m ost severely a ffected ch ildren may be re jected by the ir 
peers and even by the ir care-g ivers. Excessive an terio r d roo ling  destroys books, 
keyboards or com puters, and as such threa tens essentia l too ls  for educa tion  and 
com m un ica tion  in neuro log ica l d isab led  patients. In add ition  to cosm etic  effects, 
d roo ling  can produce  peri-ora l in fections and can im pa ir the dentition. In contrast 
to anterio r droo ling , so -ca lled  “ posterio r d ro o lin g ” refers to the spill of saliva over 
the tongue th rough  the faucia l is thm us.26 In pa rticu la r the ch ildren w ith m ost 
severe pharyngea l dysphag ia  are at m edica l risk due to saliva asp ira tion to the
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lungs. As m entioned above, asp ira tion in the ch ild  w ith CP often occu rs  w ithou t 
obv ious cough ing  or choking  (i.e. silently) and there fore chron ic asp ira tion of 
saliva m ight not be d iagnosed  prior to deve lopm ent of s ign ifican t lung injury.
In case of chem ica l irrita tion such as tha t caused by GOR, the sa livary secre tion 
is increased to pro tect the oral, pharyngea l, and oesophagea l m ucosa m ediated 
by the vago-vaga l com p lex in the brainstem . Unfortunately, in children w ith oral 
m otor dysfunction  th is pro tective increased saliva vo lum e may accum ula te  in the 
pharynx and /o r oesophagus, lead ing to an increased risk for asp ira tion. It is still 
a m atter of deba te  w hether GOR can cause severe droo ling  and w hether or not 
trea tm ent of pa tho log ica l GOR d im in ishes droo ling  in ch ildren w ith  CP.
Practical implications
In short, dysphag ia  and droo ling  are frequently  occu rring  sym ptom s and 
long-te rm  neuro log ica l sequelae. The Dutch gu ide line  fo r ch ildren w ith  spastic  
cerebra l palsy has inc luded dysphag ia  and droo ling  as im portan t issues. In our 
op in ion at early stage pa rticu la r note should be given to the im portan t con tribu tion  
tha t dysphag ia  and excessive droo ling  con tribu te  to the burden of a child w ith  CP 
and h is /her family.
This is necessary because the younger brain is a h igh ly dynam ic structure w ith 
the cap ac ity  fo r p ro found structura l and functiona l adapta tion . We th ink  tha t the 
fo rm ula tion  of rational p rognostic  s ta tem ents and deve lopm ent of appropria te  
plans for m anagem ent of dysphag ia  should be based on aw areness of the 
top og ra ph y  of the brain in jury (see tab le  2). This approach  cou ld  a lso provide 
va luab le  in form ation fo r the deve lopm ent of m ore effective in tervention stra teg ies 
for dysphag ia  in future.
A t th is  m om ent, a system atic approach  is recom m ended when c lin ic ians meet 
patien ts w ho present w ith CP. The w ork-up  needs to establish the m edica l and 
socia l consequences of the oral m otor dysfunction  and drooling . The oral m otor 
dysfunction  w h ich is often characterized as “s ile n t” asp ira tion requests an 
extended orom otor assessm ent and v id eo fluo ro scop ic  evaluation once. The 
com b ina tion  of c lin ica l features as cough ing , fever and recurrent pneum onia 
should im m edia te ly  raise the susp ic ion  of ch ron ic  pu lm onary  aspira tion, whereas 
the c lin ica l com b ina tion  of oral odour, h iccups and vom iting  m ight suggest a 
GOR disease. Both clinical conditions need a pulm onary and a gastroenterological
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Table 2 Relevance of the predilection regions for hypoxic-ischem ic neuronal 
injury to swallowing
Site of lesion Type of CPa Mental Swallowing GOR
Retardation
Oral
elements
Pharyngeal
elements
PVL Spastic +/- + +/- +/-
(sub)Cortical Spastic + + +/- +/-
Basal ganglia Dyskinetic +/- + + + +
Multicystic
encephalopathy
Spastic > 
Dyskinetic
+ + + + + + +
Abbreviations: CP = Cerebral Palsy; GOR = Gastro oesophageal reflux; PVL = Periventricular 
Leucomalacie; +/- = probably present; + = very likely present; + +  = evident 
a = most encountered
2
d iag nostic  w orkup. The trea tm ent of gut dysm o tility  and m alnu trition  can further 
help to im prove the c h ild ’s w e ll-be ing . We recom m end cons idering  trea tm ent for 
recurrent asp ira tions, GOR disease and droo ling  com p la in ts  at a very early stage, 
pre fe rab ly w ith a m u ltid isc ip lina ry  approach.
Summary Points
•  The entire sw allow ing act is b ila te ra lly con tro lled  by a com p lex neuronal ne twork 
in w h ich  the prim ary  sensory /m oto r and cingu late co rtices  play m ajor roles.
•  The cortex is not on ly involved in the in itia tion of sw allow ing but also during 
pharyngea l and oesophagea l swallow ing.
•  The sequentia l and rhythm ic patte rns of sw allow ing and related orofacia l 
behaviours (i.e. resp iration, cough ing , vom iting) are fo rm ed and organ ized by 
m u ltifunctiona l centra l pattern generators located in the brainstem .
•  The execution of the sensorim o to r aspects  of swa llow ing rely on functiona lly  
connected pathways between (extra)pyram idal co rtica l m otor p lann ing regions, 
the bra instem  con tro lling  centre, crania l nerves and lower m otor neurons.
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•  The w ide range of sw allow ing, respiration, d roo ling  and GI prob lem s in CP and 
other neuro log ica l d isorders  can be understood in relation to (partia l) d isrup tion  
of these swallow ing c ircu itries  and the b ra in -gu t axis w h ich  result in these 
disorders.
•  Excessive oral secre tions, under-nutrition, grow th fa ilure and the ins id ious 
evolution of lung disease are im portan t causes of m orb id ity  and m orta lity  in 
ch ildren w ith CP. The m u ltip lic ity  and po tentia lly  progressiveness of d isab ilities  
in CP h igh ligh t the need for a coo rd ina ted  m u ltid isc ip lina ry  program  to m anage 
bu lbar sym ptom s, resp ira to ry care and nutrition as early in the c h ild ’s life as 
possib le.
•  Many of the concep ts  d iscussed  here tha t are ap p licab le  to CP, will be also hold 
true for a w ide varie ty of o ther neuro log ica l and deve lopm enta l d isorders.
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CHAPTER 3
Abstract
O b je c tiv e : To investigate w hether droo ling  in ch ildren w ith Cerebra l Palsy (CP) in 
general and CP sub types was due to hypersalivation.
M e tho d : Saliva was co llec ted  from  61 healthy children (30 boys; mean age 9 
years and 5 m onths and 31 girls; mean age 9 years and 6 m onths) and 100 
droo ling  ch ildren (57 boys; mean age 9 years and 5 m onths and 43 girls; mean 
age 10 years and 1 month) w ith CP, of w hom  were 53 spastic, 42 dyskine tic, and 
5 ataxic. A lm ost all ch ildren were affected b ilaterally and 90 of them  had GMFCS 
levels III or higher. The saliva was co llec ted  by m eans of the swab m ethod. The 
in tensity of d roo ling  was evaluated using the D rooling Q uotient.
R esu lts : No d iffe rences were found in the flow  rates, age, or gender between 
healthy ch ildren and droo ling  CP children. At add itiona l sub -g ro up  analysis, the 
flow  rates of dysk ine tic  sub type  d iffe red s ta tis tica lly  from  healthy school children. 
C o n c lu s io n : This s tudy sup po rts  the find ing in previous stud ies tha t no hyper­
salivation exists in droo ling  CP children. D ysfunctional oral m otor contro l seem s 
to be responsib le  for saliva overflow  from  the m outh, w hereas increased 
“ unstim u la ted ” salivary flow  may occu r in dysk ine tic  CP ch ildren due to 
hyperk ine tic  oral m ovem ents.
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Introduction
Saliva is im portan t in m oisten ing the m outh and in the m aintenance of oral 
hygiene. It lubrica tes the bo lus w h ile sw allow ing and helps in regulating 
oesophagea l ac id ity .1 Saliva is p roduced  by three m ajor paired g lands -  the 
parotid , subm andibu lar, and sub lingua l g lands -  and by m inor g lands located 
th roughou t the oral and pharyngea l m ucosa. The subm and ibu la r g lands produce 
abou t 70% of high v iscos ity  resting saliva. In addition, resting saliva is com posed 
of secre tions from  the parotid  (about 25%) and sub lingua l (about 5%) glands. The 
parotid  g lands are capab le  of p roduc ing  great am ounts of w a tery saliva while 
eating and drinking. The average person swallows approx im ate ly  600 ml of saliva 
per day, a lthough in som e ind iv idua ls  it m ight be as m uch as 1000 ml per day. 
The pathway of saliva secre tion is under au tonom ic contro l. Som atosensory, 
general, and specia l v iscera l (gustatory) afferents of the Vth, VIIth, IXth and Xth 
crania l nerves term inate in the Tractus Solitarius (NTS) and sa liva to ry nucle i in the 
m edulla  ob longa ta . A con tro lling  so lita ria l-hypo tha lam ic  c ircu itry  has been 
p ro p o se d .23 The pa rasym pathe tic  stim uli enter the subm and ibu la r sa livary g lands 
by efferents of the VIIth and the parotid  g lands by efferents of the IXth. The 
p regang lion ic  sym pa the tic  fibe rs orig inate in the in te rm ed io-la tera l cell co lum n 
of the 1st and 2nd tho rac ic  cord segm ents and connect to po s tgang lion ic  nerve 
fibe rs in the superio r cerv ica l sym pa the tic  gang lion. These postgang lion ic  
sym pa the tic  nerve fibe rs reach the salivary g lands running a long the external 
caro tid  artery. The secre tion of saliva is regulated ind irectly  by the so lita ria l- 
hypo tha lam ic  c ircu itry  (“sm elling food m akes on e ’s m outh w a te r”) and by d irect 
reflexes m odula ted by tactile , m echan ica l, and gusta to ry  stim uli. The question 
rem ains w hether cerebra l pa lsy m ight include d isrup tion  of th is  regulatory 
m echan ism  as part of the encepha lopathy.
Cerebral Palsy (CP) is the m ost com m on physica l d isab ility  in early ch ildhood . It 
has been c lin ica lly  de fined as a group of motor, cognitive, and perceptive 
im pairm ents secondary  to a de fect or lesion of the deve lop ing bra in .4 A lthough 
droo ling  of saliva is usually cons idered  abnorm al in a ch ild  over four years of age, 
it has been estim ated to occu r in approx im ate ly  10% to 37% of children w ith 
cerebra l pa lsy.56 Prim ary func tions  such as lip closure, intraoral tongue  suction, 
and sw allow ing may be d is tu rbed  due to neurodeve lopm en t delay. In cases of 
saliva overflow , d is tu rbed coo rd ina tion  of tongue  m ob ility  is the m ost likely cause,
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since it is genera lly  accep ted  tha t saliva p roduc tion  rem ains w ith in  norm al limits. 
Hypersa liva tion  or hypers ia lo rrhea is rarely reported in ch ildren w ith cerebra l 
pa lsy.7-11 However, the causes of increased salivation are many: it can be an ictal 
find ing  in com p lex tem pora l lobe ep ilepsy; it can be caused by a varie ty of 
m ed ica tions or irrita ting factors, such as tee th ing , sm oking, and ga s tro eso ­
phagea l reflux; or it can be a sym ptom  in an affective disorder. 12-15 
Previous stud ies were based on sm all num bers and used ind irect m ethods (for 
exam ple, cup -like  devices or b ib -w e igh ing) to m easure the w hole saliva 
p roduction , or m easured stim ulated (gauze-chew ing or sp itting) saliva flow  rates 
in droo ling  CP children. But CP ch ildren in pa rticu la r lack the strength to chew 
well and have troub le  sp itting . Therefore, it is poss ib le  tha t the assum ption  of 
norm al saliva p roduction  is not co rrec t because of m ethodo log ica l and power 
problem s. The ob jective  of th is  case -con tro l s tudy was to determ ine w hether 
saliva p roduc tion  in droo ling  ch ildren d iagnosed  w ith cerebra l pa lsy really is 
w ith in  the norm al range. In the present study, the swab saliva co llec tion  m ethod 
(swab test) was used, th rough  w h ich  d irect and exclusive sa livary flow  
m easurem ents were possib le , tak ing  dysfunctiona l oral m otor contro l into 
accoun t. In add ition , we hypothesized tha t saliva secre tion in ch ildren w ith 
dysk ine tic  CP is increased due to added m echan ica l stim u la tion  of the salivary 
g lands as a result of hyperk ine tic  oral m ovem ents.
Method
We co llected data on 100 ch ildren (57 boys, age three to 19 years, mean age 9 
years and 5 m onths (SD 3.9) and 43 girls, age four to 19 years, mean age 10 years 
and 1 m onth (SD 4.7)) d iagnosed  w ith CP and referred to the ou tpa tien t M u lti­
d isc ip lina ry  D rooling Centre of the Radboud University M edica l Centre between 
2001 and 2007 because of m odera te to profuse drooling . The ch ildren were 
ca tegorized by CP type, the ab ility  to speak, having convuls ions, and the severity 
of m otor d is tu rbances assessed by the G ross M otor Function C lassifica tion  Scale 
(GMFCS).4 The GMFCS was proven to be a valid and reliable too l w h ich  rem ains 
relatively stab le  over tim e.1617 The ch ildren were enro lled using the inclusion and 
exclusion criteria  in Table 1. W ritten in form ed consen t was ob ta ined from  all 
parents. The research was conducted  in acco rdance  w ith the national and
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Table 1 Inclusion and exclusion criteria 
Inclusion criteria
Children (male and female, age 3-19 years).
Confirmed diagnosis of cerebral palsy (medical history and neurological examination, 
MRI, EEG).
Score of three or higher on the Drooling Severity and Frequency Scale, indicating 
moderate to profuse drooling.
Informed consent (parents/caregiver).
Exclusion criteria
Enrolment in another medical study.
Previous surgical procedure for saliva control.
Use of drugs that interfere with saliva secretion (anticholinergic and neuroleptic drugs, 
benzodiazepines).
3
in te rnationa l eth ical s tandards and the H o sp ita l’s Hum an Research com m ittee  
approved the study.
The contro l g roup consis ted of 61 healthy ch ildren recru ited from  prim ary schools, 
ranging in age from  e ight to 12 years: 30 boys (mean age 9 years and 5 months; 
SD 0.9) and 31 girls (mean age 9 years and 6 m onths; SD 1.2). None of the 
ch ildren reported having any com p la in ts  suggestive  of sa livary g land dysfunction  
or needed any m edication that w ould influence the salivary secretion. The parents 
of all ch ildren gave w ritten in form ed consent. The data for the contro l g roup were 
co llec ted  at the s tart of the study in 2001 and the results were pub lished earlier.18 
Saliva was co llec ted  under standard ized cond itions  using the m ethod described 
by Rotteveel et al in 2004.18 A fte r the m outh was dried w ith sterile gauze, three 
absorben t co tton  rolls (Salivette® , Sarstedt BV, Etten-Leur, The Netherlands) 
were p laced in the m outh for five m inutes: one roll under the tongue at the orifices 
of the ducts of the sub lingua l and subm and ibu la r g lands and tw o rolls in the 
upper vestibu les  at the open ings of each parotid  duct. In the present study, we 
labe led all flow  in the floo r of the m outh as subm and ibu la r flow. The co tton -ro lls  
were w e ighed before and after the procedure  using an e lectron ic  scale, w h ich
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was sensitive to 0.01 g. The increase in w e igh t during the five m inutes interval was 
then converted into ml saliva/m in . The droo ling  in tensity was evaluated by the 
D rooling Q uotien t (DQ), a d irect sem i-quan tita tive  observa tiona l m ethod. 1920 
Every 15 seconds (40 observa tions in 10 m inutes) the presence of new ly form ed 
saliva on the lips was assessed. The DQ is expressed as a percen tage estim ated 
from  the ratio of observed droo ling  ep isodes  and the to ta l num ber of observations. 
Both the swab testing and the DQ m ethod were perfo rm ed in healthy school 
ch ildren and droo ling  ch ildren w ith CP in the m orn ing at least one hour after the 
last meal, w h ile they were w atch ing  te levis ion. M easurem ents were perfo rm ed by 
tw o  experienced speech language therapists.
Statistical analysis
The subm and ibu la r and parotid  flow  rates were com pared  between the healthy 
schoo l ch ildren and the children w ith  CP using non-param etric  s ta tis tics 
(M ann-W hitney U and K ruskal-W allis tests), because of non-norm al d is tribu tions 
for these param eters, espec ia lly  in the CP children. All pa rtic ipan ts  were 
ca tegorized by gender and age. Because of the w ider age range in CP children, 
the CP group was sp lit up in three age groups (three th rough  seven years, eight 
th rough  12 years, and 13 th rough  19 years of age). In add ition , the to ta l CP group 
was subd iv ided  into spastic  and dysk ine tic  CP sub types. The m agnitude of the 
assoc ia tions  between the DQ and the to ta l sa livary flow  for all CP ch ildren and for 
the CP sub types was assessed using the Spearm an rank corre la tion  coe ffic ien t. 
All analyses were perfo rm ed w ith SPSS 14.0 for W indows. Results w ith tw o-ta iled  
p -va lues  <0 .05  were cons is ted s ta tis tica lly  sign ificant.
Results
A lm ost all ch ildren d iagnosed w ith CP (53 spastic, 42 dyskinetic, and 5 ataxic 
sub types) were a ffected b ilaterally and 90 ch ildren had a score of III or h igher on 
the G ross M otor Function C lass ifica tion  Scale (GMFCS). Ep ilep tic  seizures were 
in contro l in 46 ch ildren and on ly four ch ildren suffered from  in tractab le seizures. 
F ifty ch ildren had never had any convu ls ions at all. O nly one ch ild  had norm al
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articu la tion , w hereas 37 ch ildren had dysa rth ric  speech and 62 were anarthric  
(Table 2). All ch ildren w ith CP had a score of three or h igher on a droo ling  severity 
and frequency scale, ind ica ting  m odera te to pro fuse d ro o ling .21 Each child had 
som e kind of oral m otor dysfunction  such as tongue protrusion, m alocclus ion, 
reduced intra-oral sensitivity, or reduced ability to voluntarily control the movements 
of lips, tongue, and jaw.
Table 2 Patients characteristics
Number Total 100
CP subtype Spastic 53
Dyskinetic 42
Ataxic 5
Affected side Unilateral 2
Bilateral 98
Convulsions None 50
Controlled 46
Intractable 4
Medications All anti-epileptic drugs were allowed, except benzodiazepines
Speech Unimpaired 1
Dysarthric 37
Anarthric 62
GMFCS I 3
II 7
III 24
IV 34
V 32
Legend to table 2: CP = Cerebral Palsy; GMFCS = Gross Motor Functional Classification Scale 
(I = performing gross motor skills including running and jumping but reduced speed, balance, and 
coordination, II = limitations walking on uneven surfaces and inclines, and walking in crowds or 
confined spaces, III= walking indoors or outdoors on a level surface with an assistive mobility device, 
wheelchair as needed, IV = reliance on wheelchair,
V  = no means of independent mobility)
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All ch ildren cou ld  perform  the swab testing  and no one had to be w ithdraw n from  
our study. In healthy school children the m edian subm and ibu la r flow  rate was 
0.32 m l/m in (range 0.10-0.56), w hereas the m edian parotid  flow  was 0.11 m l/m in 
(range 0.02-0.44). The m edian subm and ibu la r flow  rate in ch ildren w ith CP was 
0.34 m l/m in (range 0.08-1.09) and the m edian parotid  flow  0.14 m l/m in (range 
0.00-0.60) (see Table 3). Neither the subm and ibu la r flow  rates (p =  0.331) nor the 
parotid flow  rates (p =  0.373) were s ta tis tica lly  s ign ifican tly  d iffe rent between the 
healthy school ch ildren and the CP children.
Table 3 Results
Controls CP Spastic CP Dyskinetic CP
N 61 100 53 42
Subm (ml/min) 0.32 0.34 0.34 0.38
p-va lue 0.331 0.873 0 .047*
Par (ml/min) 0.11 0.14 0.10 0.18
p-va lue 0.373 0.583 0 .040*
DQ (%) 0.0 23.2 20.0 31.9
p-va lue 0.015*
Legend to table 3: N = Number; Subm = Submandibular flow (ml/min); Par = Parotid flow (ml/min); 
DQ = Drooling Quotient (%); CP= Cerebral Palsy; * statistically significant different.
The mean ages of the school children (9 years and 6 months; SD 1.0) and the CP 
children (9 years and 8 m onths; SD 4.2) were not d iffe rent (p =  0.846), but the 
age range of the CP group was m uch w ider than that of the healthy school 
children. However, there were no d iffe rences in the subm and ibu la r flow  rates 
between the three age groups of d roo ling  CP ch ildren (p =  0.749). The m edian 
parotid flow  rates d iffe red som ew hat between the three age groups (p =  0.017), 
po in ting tow ards lower flow  rates am ong ch ildren in the o ldest age group. No 
d iffe rences existed in gender between the con tro ls  and the CP ch ildren (p =
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0.336), nor in the m edian sa livary flow  rates between contro l g irls and g irls w ith 
CP (subm andibu lar p  =  0.801, parotid  p  =  0.622) and between con tro ls  boys and 
boys w ith CP (subm andibu lar p  =  0.195, parotid  p  =  0.099).
No d iffe rences were found in gender (p =  0.288) and mean age (p =  0.428) 
between the spastic  and dysk ine tic  CP sub types. The m edian subm and ibu la r 
and the parotid flow  rates in the spastic  sub type  were 0.34 m l/m in (range 
0.08-0.68) and 0.10 m l/m in (range 0.00-0.60). In the dysk ine tic  sub type, the 
m edian subm and ibu la r and parotid flow  rates were 0.38 m l/m in (range 0 .08­
1.09) and 0.18 m l/m in (range 0.02-0.48), respectively. The parotid flow  rate was 
s ta tis tica lly  s ign ifican tly  d iffe rent between the spastic  and dysk ine tic  sub types 
(p =  0.029), w hereas the d iffe rence between the subm and ibu la r flow  rates (p =  
0.069) a lm ost reached sta tis tica l s ign ificance . No d iffe rences were found in the 
sa livary flow s between the con tro ls  and the spastic  CP children. However, the 
sa livary flow s were s ta tis tica lly  s ign ifican tly  d iffe rent between the healthy school 
ch ildren and the ch ildren w ith  dysk ine tic  CP (subm andibu lar p  =  0.047, parotid 
p  =  0.040) (see Table 3)
The m edian DQ in the drooling children with CP was 23.2 % (range 0.0-81.0 %). The 
difference in the DQ between the spastic subtype (20.0 %; range 1.8-81.3 %) and the 
dyskinetic subtype (31.9 %; range 0.0-76.3 %) was statistically significant (p =  0.015). 
A mild correlation (spearm an’s rho =  0.28; p =  0.004) existed between the total 
salivary flow in the drooling CP children and the DQ (Figure 1). The correlation 
between the total flow and the DQ in spastic CP children was also mild (spearm an’s 
rho =  0.38; p =  0.005), but there was no correlation between the total flow and the 
DQ in the dyskinetic CP subtype (spearm an’s rho =  0.07; p  =  0.683).
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Figure 1 The m agnitude and direction of the association between the
total salivary flow and the Drooling Quotient in all children with CP 
(Spearman's rho =  0.28)
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Discussion
The present s tudy did not show  substantia l d iffe rences in the salivary 
subm and ibu la r and parotid flow  rates between healthy schoo l children and 
droo ling  CP children in general, nor between age and gender. However, the 
results did show  d iffe rences in the flow  rates between healthy school ch ildren and 
the dysk ine tic  CP subtype. D rooling in ch ildren w ith dysk ine tic  CP is m ore intense 
in com parison  to ch ildren w ith  spastic  CP, but does not seem to be corre lated 
w ith  the to ta l sa livary flow.
To our know ledge, the present case -con tro l s tudy on droo ling  is the largest study 
pub lished so far, w ith as m any as 161 pa rtic ipan ts  m easured w ith the swab saliva 
co llec tion  m ethod a llow ing us to ca lcu la te  the saliva secre tion per sa livary gland. 
W ith these num bers, we were ab le to de tect d iffe rences of half the standard 
devia tion for both the subm and ibu la r and the parotid  flow s w ith a power of 80%.
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It rem ains d ifficu lt however, to s tudy a he terogeneous popu la tion , such as children 
w ith  cerebra l palsy. A lthough, th is  he terogene ity  gave us the op po rtu n ity  to look 
at sub types of CP, it m ay be an im portan t lim ita tion  of the study, as it may have 
m asked other d iffe rences. On the other hand, all cases were well defined and the 
contro l g roup and patient g roups m atched in gender and mean age. However, 
the age range in the CP group was m uch w ider than in the contro l group, no 
age-re la ted decline  or increase in the d is tribu tion  of the sa livary subm and ibu la r 
flow s was noted in the ch ildren from  three up to 19 years of age, but the parotid 
flow s seem ed som ew hat unstab le over the age groups. Despite num erous 
stud ies on sa livary flow  rates, the e ffect of ageing on sa livary secre tion rem ains 
obscure  due to con flic ting  observa tions. One s tudy found tha t the unstim ulated 
parotid  flow  rate increased s ign ifican tly  w ith increasing age in ch ildren ranging 
from  three to 16 yea rs22, whereas other stud ies suggested tha t high salivary 
ac tiv ity  in school ch ildren decreased w ith increasing age23 or reported no 
age-re la ted decline  or increase of unstim ulated sa livary flow  in e igh t to 12-years- 
o lds.18 Apparently, age is not an im portan t fac to r w hen m easuring sa livary flow  
rates up to adolescence.
In o ther stud ies on droo ling  CP children, the to ta l am ount of s tim ulated saliva was 
co llec ted  by cup -like  devices or by a gauze-chew ing  procedure  or b ib -w e igh ing  
techn ique .11,22 These stud ies dem onstra ted the in fluence of d is tu rbed oral m otor 
contro l on droo ling  in children w ith CP. Senner suggested tha t d roo ling  CP 
ch ildren sw allow  less frequen tly .22 Sochan iw skj et al dem onstra ted a d im in ished 
ab ility  to contro l the oral phase of sw allow ing and prob lem s in the coo rd ina tion  of 
the sequence of m uscle activa tion  in sw allow ing. All CP children, both those who 
drool and those who do not, had a d im in ished subconsc ious  swallow ing 
frequency.9 Lespargot suggested tha t an initial oral suction  stage is abnorm al in 
all d roo ling  CP children, w h ich  m ight be a fac to r tha t leads to poo ling  in the oral 
cavity .8 Tahm assebi and Cruzon found som e kind of d is tu rbed oral m otor contro l 
m ost o ften characterized by incom ple te  lip-c losure , tongue  pro trusion, stiff and 
slow  tongue m ovem ent, lack of vo lun ta ry  contro l of jaw  and tongue, and oral 
dyskinesia .11 This m ight be cons is ten t w ith a d is tu rbance  in the sw allow  c ircu its  as 
m entioned in the in troduction. So, when studying droo ling  in CP children, it seem s 
adv isab le  to cons ide r the in fluence of dysfunctiona l oral m otor contro l. Using the 
absorben t swab testing m ethod, any urge to sw allow  can be left out of 
cons idera tion  due to the position  of the co tton -ro lls  ad jacent to the orifices of the
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ducts  of the sa livary g lands, preventing any leakage of saliva in the oral cavity. 
The swab m ethod has proven to be a h igh ly rep roduc ib le  m ethod and it has been 
reported  tha t the co tton -ro lls  m ethod in hand icapped  ch ildren is a useful too l to 
evaluate the unstim ulated sa livary flow  rate of both the subm and ibu la r and parotid 
g lands.18 24 Unlike previous stud ies, we were ab le to m easure the unstim ulated 
sa livary flow  d irec tly  and exclusively, independent of any kind of swa llow ing 
dysfunction . However, any hyperk inetic  oral m otor ac tiv ity  cou ld  not be ruled out 
or prevented.
Despite the fact tha t we did not find argum ents fo r hypersa liva tion in the tota l CP 
group, c lin ica lly  the droo ling  ch ildren w ith dysk ine tic  CP appear to be a subgroup. 
Due to m echan ica l stim u la tion  of the sa livary g lands in these children, the tota l 
da ily  saliva secre tion (about 600 ml in general) was increased by an am ount of 
approx im ate ly  200 ml per day or even more. The con tribu tion  in added saliva 
secre tion of the parotid  g lands was tw ice  as large as tha t of the subm and ibu la r 
g lands. This can be a relevant phenom enon in the m anagem ent of droo ling . In 
o ther words, trea tm ent of d roo ling  in spastic  CP children should m ainly be 
focused  on the saliva flow  of the subm and ibu la r/lingua l g lands, w h ile in dyskine tic  
CP the ta rge t seem s to be both the subm and ibu la r/lingua l and parotid flows.
Conclusion
This s tudy suppo rts  the find ing in previous stud ies tha t no hypersa liva tion exists 
in droo ling  CP children in general. However, there are argum ents fo r increased 
sa livary flow  in droo ling  dysk ine tic  CP ch ildren due to hyperk inetic  oral m otor 
activity. In con tras t to previous stud ies, th is  has been suppo rted  by d irect 
m easurem ents of resting “ un s tim u la ted ” salivation in a large popu la tion  using a 
m ethod that decreased potentia l in fluences of oral m otor contro l d is tu rbances.
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CHAPTER 4
Abstract
Objective To address the efficacy of Botulinum Toxin and the duration of its effect 
when used on a large scale for the treatment of drooling in children with 
neurological disorders.
Design Prospective cohort study.
Setting Academic multidisciplinary drooling clinic.
Patients A total of 131 children diagnosed as having cerebral palsy or another 
nonprogressive neurological disorder and who also have moderate to severe 
drooling.
Intervention Injection of Botulinum Toxin to the submandibular glands.
Main Outcome Measures Direct observational drooling quotient (DQ) (0-100) 
and caretaker visual analog scale (VAS) scores (0-100).
Results A clinically notable response was found in 46.6% of children, reflected in 
a significant mean reduction in DQ from a baseline of 29 to 15 after 2 months and 
19 after 8 months (P < .001). The mean VAS score decreased from 80 at baseline 
to 53 after 2 months and increased to 66 after 8 months (P < .001). Kaplan-Meier 
analysis showed that patients who initially responded to treatment experienced 
relapse after a median of 22 weeks (interquartile range, 20-33 weeks). 
Conclusions Our study provides further support for Botulinum Toxin’s efficacy for 
treatment of drooling in approximately half of patients for a median of 22 weeks. 
Further optimization of patient selection should be an area of attention in future 
studies.
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Introduction
Drooling is a common problem for children with neurological disorders. Recent 
estimates suggest a prevalence of nearly 60% in children in special care school, 
of which 33% could be classified as severe.1 Drooling in these children is usually 
caused by a combination of low oral sensitivity, infrequent swallowing, poor 
posture and mental ability, and dysfunctional oral motor control leading to 
excessive pooling of saliva in the anterior oral cavity and consequently to 
unintentional saliva loss.2-3 Hypersalivation might only be an issue in children with 
dyskinesia as a result of hyperkinetic oral movements.4
The morbidity associated with sialorrhea has long been established in the 
literature.5-8 Depending on the associated neurological disorder, cognitive 
abilities, and oral motor function, affected children may experience anything from 
stigmatization and social neglect to numerous daily clothing changes, perioral 
dermatitis, aspiration pneumonia, or even dehydration. The management of 
drooling has long been a matter of debate. Speech therapy and behavioral 
therapy have been proposed, but our clinical experience suggests that this is only 
useful in children with sufficient cognitive abilities to train.9 Treatment with 
systemic anticholinergics appears to be effective, but these drugs are associated 
with notable adverse effects.10 Various surgical techniques have been reported to 
be highly effective, but owing to their invasive and often irreversible nature, other 
treatment techniques should be attempted first.
Intraglandular Botulinum Toxin, therefore, offered a promising treatment option 
when first suggested a decade ago.11 Its localized nature and strong anticholiner­
gic properties offered the potential to reduce drooling without the invasiveness of 
surgery. The intervention was subsequently demonstrated to be effective in a 
large number of studies, with most authors finding a clinically significant reduction 
in unwanted saliva loss in 33% to 64% of patients for approximately 2 to 6 months.12 
Botulinum Toxin has been in use in our multidisciplinary drooling clinic since 
1999. Our group has previously reported our initial results elsewhere.13-15 Our 
present aim is to report on the efficacy and duration of effect of Botulinum Toxin 
when used on a larger scale in clinical practice.
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Methods
Participants
Children eligible for inclusion were diagnosed as having cerebral palsy or another 
nonprogressive neurological disorder and were seen in our multidisciplinary 
drooling clinic for moderate to severe drooling. For each patient, conservative 
measures had not had sufficient effect or were not feasible, and injection of 
Botulinum Toxin to the submandibular glands was recommended as treatment. 
Full inclusion and exclusion criteria, including Teacher Drooling Scale16 score, are 
listed in Table 1.
Study design
Patients were enrolled consecutively between January 2000 and July 2008. 
Assessment of the severity of drooling took place under standardized conditions 
before treatment and 8 and 32 weeks after treatment. This allowed for a within- 
subjects design in which the patient’s baseline condition was used as a reference 
to evaluate the effects of injection over time.
Procedures
For the injection of Botulinum Toxin, children were under general anesthesia. A 
single dose of Botulinum Toxin type A (Botox; Allergan, Nieuwegein, the 
Netherlands), reconstituted with 0.9% sodium chloride, was then injected into the 
submandibular glands using a 25-gauge needle and a 1-mL syringe. The 1-mL 
volume was chosen to allow the dose to be fractionated over at least 3 sites in the 
gland while minimizing the risk of diffusion into surrounding tissues. We used 15 
U of Botulinum Toxin per gland for children weighing less than 15 kg, 20 U/gland 
for children weighing between 15 kg and 25 kg, and 25 U/gland for children 
weighing more than 25 kg. During injection, the dose was fractionated over at 
least 3 sites in the gland under ultrasonographic guidance. The sublingual glands 
and parotid glands were not treated.
Outcome measures
The drooling quotient (DQ), a validated, direct-observational semiquantitative 
method to assess the severity of drooling served as the primary outcome measure 
for both efficacy and duration of effect.14 The DQ was defined as the percentage
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Table 1 Inclusion and exclusion criteria
Inclusion criteria
Non-progressive congenital neurological disease.
Invalidating drooling (TDS > 3).
Treated with Botulinum Toxin to the submandibular glands at least once. 
Exclusion criteria
Known hypersensitivity to Botulinum Toxin or any part of the formulation. 
Missing baseline measurement, or missing >1 follow-up measurement. 
Known use of other agents that influence drooling during the treatment. 
Progressive disease.
of time the patient drooled and was measured by 1 of 2 specially trained speech 
language therapists. During two 10-minute sessions (one while the patient was 
concentrating and the other while the patient was distracted), the absence or 
presence of new saliva on the lip was recorded every 15 seconds for a total of 40 
observations per session. Patients were evaluated in the morning, at least 1 hour 
after a meal, while they were awake and sitting upright. Response to treatment 
was defined as a 50% reduction in DQ from the baseline value.
A caretaker visual analog scale (VAS) score reflecting the severity of drooling over 
the previous 2 weeks served as secondary outcome measure. Caretakers marked 
the extent of drooling on a 10-cm line following specific instruction. The VAS score 
was obtained by measuring the position of the mark in millimeters from the right 
end of the scale on a scale from 0 to 100, with 100 corresponding to severe 
drooling. A reduction of 2 SDs from the baseline VAS score was considered 
clinically significant.
Finally, qualitative assessments were made throughout the study of oral hygiene 
(including xerostomia), saliva viscosity, feeding behavior, and speech.
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Statistical analysis
Statistical analyses were performed using SPSS software, version 16.0.2.1 for 
Mac OS X (SPSS Inc, Chicago, Illinois). For analysis of the DQ and VAS score, we 
used descriptive statistics; conducted paired t tests to assess differences of 
paired observations; performed independent t tests and linear regression to 
compare groups; and performed a multivariate analysis of variance with a 
repeated measures design to evaluate the treatment response pattern over time, 
using a within-subjects design with the measurement moments as the variables. 
Missing follow-up data were adjusted in 2 ways: (1) by carrying the last observation 
forward (CLOF) and (2) through a worst-case scenario (WCS). In the CLOF 
procedure, missing data were replaced with the last previous observation; in the 
WCS procedure they were replaced by baseline values, thus introducing a bias 
toward the null. The outcomes of both approaches are presented herein. Analysis 
of the duration of the effect of Botulinum Toxin injection was accomplished by 
observing patients who were classified as responders beginning 8 weeks after 
intervention and performing a time-to-event (Kaplan-Meier) analysis until relapse 
occurred. The interval between the last known date of success and the end date 
was halved to compensate for the gradual loss of effect associated with Botulinum 
Toxin. All tests of significance were 2 sided, and P .05 was considered statistically 
significant.
Results
A total of 133 children were initially included. One was subsequently excluded 
because of a missing baseline assessment, and another for a complete lack of 
follow-up data. This left 131 children suitable for analysis, 77 boys and 54 girls. 
The mean (SD) age at the time of treatment in this group was 10.9 (4.7) years (age 
range, 3-27 years). Most of the patients were diagnosed as having cerebral palsy 
(90.1%), while the others had psychomotor retardation of unknown origin. Over 
half of the children had a Gross Motor Function Classification System score of 4 
or higher, indicating that they relied on a wheelchair for mobility. A total of 41.2% 
of them had well-controlled epilepsy, and another 14.5% had intractable epilepsy.
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Primary outcomes
The follow-up rate at the 2-month interval (median interval, 8 weeks; interquartile 
range [IQR], 8-9 weeks) was 97.8%, and at the 8-month interval (median interval, 
32 weeks; IQR, 31-34 weeks) it was 94.0%. No evidence was found of selective 
loss of follow-up. Analysis of the DQ was first performed on the data adjusted by 
CLOF. Repeated measures analysis showed a highly significant reduction 
(Hotelling Trace F = 38 360, P < .001), depicted in Figure 1. At the first follow-up, 
the mean DQ had fallen from a baseline value of 28.8 to 15.5, a change of -13.3 
(P < .001). Sixty-one patients experience a 50% reduction in DQ from baseline 
and so were considered “responders” by our definition. Although follow-up after 
8 months showed the beginning of a return to baseline, there was still a significant 
difference compared with the baseline assessment (-10.0) (P < .001). As a result 
of the high follow-up rate, WCS analysis did not yield notably different results 
(F = 38 878, P < .001). Patient sex (P = .10), neurological score (P = .07), or age
Figure 1 From a mean baseline value of 28.7, the DQ showed a statistically 
significant mean reduction to 15.5 after 2 months and 18.7 after 
8 months (P < 0.001)
CLOF, for last observation carried forward; 
WCS, worst-case scenario.
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(P = .32) did not significantly influence outcome. Detailed time-to-event analysis 
was subsequently performed for the 61 responders at the 2-month follow-up to 
investigate the duration of the effect provided by Botulinum Toxin. Disease-free 
survival was defined as the time the DQ remained below 50% of baseline values, 
and no repeated intervention was indicated or performed. Kaplan-Meier analysis 
showed a median duration of effect of 150 days (22 weeks) (Figure 2). An IQR of 
138 to 235 days (20-34 weeks) indicated that 75% of patients who initially 
responded well to therapy stopped demonstrating a clinically significant effect 
before 8 months after injection. Four patients were lost to follow-up before relapse 
could be established (right-censored observations). At the last observation, these 
patients still experienced an ongoing effect, and the duration of effect in these 
cases is thus not known.
Figure 2 Kaplan-Meier analysis of longevity of Botulinum Toxin injection for 
patients who showed a response to Botulinum Toxin after 8 weeks 
(n=61)
Duration (days)
Duration of effect shown in days. Median: 150, IQR: 138-235.
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Secondary outcomes
For 3 patients, VAS scores could not be analyzed owing to a missing baseline 
score. Analysis of the remaining 128 children showed a significant pattern similar 
to the DQ (F = 58 804, P < .001), which is depicted in Figure 3. After 2 months, 
the mean VAS score had fallen from a baseline value of 80.4 to 53.9 (P < .001). 
After 8 months, the VAS score had risen to 65.7 (P < .001) (Table 2). Although 
there were more missing VAS score values (6 after 2 months, 20 after 8 months) 
than DQs, no meaningful differences were found between the CLOF and WCS 
analyses; only the 8-month score was slightly higher in the WCS setup (68.8). 
Response rates, defined as a reduction of 2 SD from the baseline score, were 
51.0% after 2 months and 26.0% after 8 months.
Figure 3 From a mean baseline value of 81.2, the VAS fell to 53.3 two months 
after injection (P < 0.001). After 8 months, the value of 69.7 was still 
significantly lower than at baseline (P < 0.001)
85
-© -C L O F  
“  TÉT - WCS
50
baseline 2 months 8 months
tim e
CLOF, for last observation carried forward; WCS, worst-case scenario.
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Table 2 Mean differences between baseline and follow-up measurements
Pairs of 
observation DQ - difference (95%-CI) VAS - difference (95%-CI)
CLOF WCS CLOF WCS
Bl-2 months -13.2 -13.2 -23.5 -23.6
(-16.2 - -10.1) (-16.2 - -10.1) (-29.3 - -17.5) (-29.6 - -17.5)
Bl-8 months -9.9 -10.0 -12.1 -15.3
(-12.9 - 6.9) (-13.0 - -7.1) (-17.3 - -7.0) (-21.1 - -9.7)
2 months-8 3.2 3.2 12.2 15.4
months (0.8 - 5.7) (0.7 - 5.7) (7.1 - 17.3) (9.7 - 21.1)
Bl indicates baseline; CLOF, carry observation forward; WCS, worst-case scenario. 
Based on paired-samples f-tests, 2-sided P < 0.05.
Although injections were usually well tolerated, there were several minor adverse 
effects in this series. Changes in the viscosity of saliva were perhaps the most 
common side effect of treatment: 54 children experienced thickening of saliva at 
some point as noticed by parents or detected by clinicians at follow-up (41.2%). 
Interestingly, a reduction in saliva viscosity was reported 16 times (12.2%). 
Transient difficulty in swallowing was reported by 4 patients (3.1%), presumably 
mostly as a result of altered saliva consistency, although diffusion of toxin 
into surrounding tissue cannot be excluded as a cause. Eight children showed 
temporarily deteriorated feeding behavior (6.1%), while 9 patients showed 
improved feeding (6.9%). Two patients reported xerostomia after 2 months (1.7%), 
which had resolved after 8 months.
Secondary beneficial effects following injection included improved oral hygiene 
(reduced perioral dermatitis or reduction in halitosis) in 4 patients (3.1%) and improved 
speech in another 4 patients. These effects generally disappeared after 8 months.
Comment
To our knowledge, this is the largest described series of patients treated for 
drooling with intraglandular Botulinum Toxin. In these 131 patients, we found an
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objective and subjective response rate of approximately 50%, similar to that found 
in smaller studies. Responders benefited from injection for a median of 22 weeks. 
After 33 weeks, 25% of initial responders (11.3% of the entire population) still 
showed a clinically significant response to the toxin, with a handful of patients 
experiencing continued drooling relief after 1 year.
Morbidity associated with the procedure was limited. Changes in the viscosity of 
saliva were reported very frequently but rarely led to severe problems, perhaps 
partially as a result of the dietary advice given to caretakers to provide only 
food that was easily mashed or melted for several days following injection. 
Only 2 patients reported xerostomia, indicating that saliva production from the 
sublingual, parotid, and minor salivary glands was usually sufficient to maintain 
a physiologically moist oral cavity.
No predictors for successful treatment were found in this series, although it 
should be noted that this was not a primary objective of the present study. Motor 
function was expected to correlate with outcome, but this was not confirmed by 
these data. A larger sample might be required to detect this; alternatively, other 
factors might influence response to therapy, such as posture, oral motor function, 
or diet, data for which were not available for this study. It thus remains unclear 
why some patients benefit so much more or so much longer from Botulinum Toxin 
injection than others. As many patients are currently treated without experiencing 
meaningful benefits, more information on factors influencing outcome and 
duration of effect would be very useful.
It should be noted that injections in our study were limited to the submandibular 
glands; these are responsible for 70% of resting saliva production. The parotids 
mainly secrete during mastication. However, combined injections to the 
submandibular and parotid glands appear to be used more frequently.17-19 Our 
clinical experience hints that combined injections could indeed be slightly more 
effective than isolated submandibular injections, but there is currently little 
scientifically sound evidence to support or disprove this impression.
Another important issue surrounding the application of Botulinum Toxin is still the 
effect of repeated injections. Prolonged denervation of salivary glands induces 
atrophy of the gland,20 and it has been hypothesized that chemical denervation 
via repeated Botulinum Toxin injection could bring about a similar effect and thus 
lead to a permanent reduction in drooling.14 On the other hand, a recent report 
has described secondary nonresponse to Botulinum Toxin type B following
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repeated injection, implying that there may be a limit to the number of effective 
treatments with Botulinum Toxin for some patients.21 Systematic studies in this 
area, however, have yet to appear.
Until evidence for a cumulative effect appears, Botulinum Toxin should therefore 
be considered a temporary solution to relieve drooling, as the current study 
underscores. In our tertiary center, submandibular Botulinum Toxin is used as a 
first-line treatment for patients for whom oral motor training or behavioral therapy 
have failed or are not considered feasible. Renewed injections are considered on 
a case-by-case basis. Combined parotid and submandibular injections are 
generally reserved for patients with a severely inadequate swallowing mechanism 
and suspected aspiration or for patients who have not sufficiently responded to 
submandibular injections. We prefer not to give combined injections to children 
who are fed orally because the diminished food bolus lubrication might pose a 
risk in children for whom ample saliva is just barely enough. Reducing salivary 
flow too much in such cases could potentially impair oral feeding. Surgery is 
advised if (1) the patient has reached an age when it is unlikely that further 
development will cure the drooling (usually from approximately 12 years), (2) 
drooling persists despite repeated Botulinum Toxin injection, or (3) patients 
express a desire for a permanently effective solution. We believe that systemic 
anticholinergic therapy should be prescribed with great caution because (1) it 
carries the risk of serious adverse effects and (2) the less risky localized anti­
cholinergic therapy via Botulinum Toxin can be quite effective.
Although the observational nature of our study makes it difficult to make definitive 
statements about the magnitude of Botulinum Toxin’s effect, our results provide 
further support for the clinical efficacy of Botulinum Toxin for drooling in patients 
with nonprogressive neurological disease. Furthermore, they indicate that most 
patients who initially respond well to injection can expect an effect to last between 
19 and 33 weeks. Although the 46.6% success rate might appear low, its safety 
and efficacy make Botulinum Toxin a useful first-line invasive treatment if 
conservative measures have failed. Improved patient selection could perhaps 
increase the response rate. This, together with the effectiveness of repeated 
injection and combined parotid/submandibular injection should therefore be 
areas of specific attention in future studies.
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CHAPTER 5
Abstract
The aim of this study is to define factors that influence therapy outcome of 
submandibular Botulinum Toxin injections for drooling in children with cerebral 
palsy and / or mental disability.
It is postulated that differences in response may be explained by the variation of 
dysfunctions in the various cerebral palsy subtypes.
Prospectively collected data were evaluated of 80 spastic and 48 dyskinetic 
children, of whom 70% had an IQ < 70. In addition the data of 23 fully ambulant 
children with exclusively mental disability were examined.
Flow and Drooling Quotient were assessed at baseline and at 8 weeks after 
injection. Following treatment both the Drooling Quotient and submandibular flow 
decreased in all children. Morbidity associated with the procedure was limited. 
Ninety three children responded to Botulinum. Decrease of submandibular flow in 
these children was associated with reduction of parotid flow. In the non­
responders, spread across all three diagnostic classifications, parotid flow 
increased after injection. Response failure is characterized by increased parotid 
flow after injection, however the precise role of parotid flow in therapy failure 
remains unclear. We cannot predict who will respond to Botulinum Toxin to treat 
drooling.
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Introduction
Drooling is normal in the growing child up to the age of 18 months. Beyond the 
age of four years it is abnormal and frequently persists in children with poor 
neuromuscular coordination, mental disabilities, as well as in children who lost 
the structural integrity of their jaws, lips or oral cavity.1 It is widely accepted that 
drooling in Cerebral Palsy (CP) is caused by oral motor dysfunction.2-5 An 
exception to this may be for those with dyskinetic disorders where the abnormal 
oral movements may constantly stimulate the parotid glands to produce more 
saliva.2 Moreover, the risk of oromotor disorders and excessive drooling increases 
in wheelchair-bound persons and in children with any degree of intellectual 
impairment.6 The inadequate swallowing of saliva may increase the risk of 
aspiration as well as contributing to impaired communication due to the constant 
presence of saliva.
In several prospective, controlled clinical trials significant reduction of saliva with 
a maximum response at 2 to 8 weeks was found after Botulinum Toxin type A 
injection.7 Botulinum Toxin inhibits the acetylcholine release at the autonomic 
terminals of the salivary glands decreasing the secretion of water. However, after 
10 years experience in our multidisciplinary drooling clinic it was observed that up 
to 30 percent of the children the drooling severity and frequency did not change 
significantly after submandibular Botulinum Toxin A injection. In our previous 
study we suggested that increased saliva production due to constant stimulation 
of the parotid glands due to hyperkinetic oral movements might account for 
drooling in those with dyskinetic disorders. In addition, peripheral sympathetic 
inhibition of salivary reflex secretion has been described as being related to 
non-physiological conditions, for instance after Botulinum Toxin application.8 
To evaluate these possibilities the present cohort study explored the effect of 
submandibular Botulinum Toxin type A at the parotid salivary flow in three distinct 
clinical groups of children: children with spastic CP, dyskinetic CP and mental 
disability without CP. We hypothesized that treatment efficacy will be similar 
across all three groups with similar rates of responsiveness.
In view of the anticholinergic property of Botulinum Toxin, it is likely that the watery 
component of saliva will be reduced and that after receipt of Botulinum Toxin, the 
salivary viscoelasticity increases.9 Interesting, it has been reported that saliva 
viscosity reduces after Botulinum Toxin injections.10 The opposite phenomenon
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(much thinner salivary aspect post Botulinum Toxin) may indicate that the reflex 
salivary secretion from other salivary glands increases after submandibular 
Botulinum Toxin type A. As such, we subhypothized that non-responsiveness to 
submandibular Botulinum type A may be caused by compensatory parotid flow.
Materials and Methods
Data from 126 individuals (age 3-21 years, mean age 10 years (y) and 11 month 
(mo) (SD 4y and 11 mo); 81 males and 45 females) who were screened at the 
outpatient drooling clinic of the Radboud University Nijmegen Medical Center, 
The Netherlands and had undergone treatment with an injection of Botulinum 
Toxin type A into the submandibular glands between February 2000 and October 
2008 were analyzed. Children were categorized as having CP or mental disability 
based upon Developmental Age11 and the severity of motor disturbances as 
assessed by the Gross Motor Function Classification System (GMFCS).12,13 The 
children with CP were subdivided by the predominant motor type.14 All of the 
children demonstrated moderate to severe dysfunctional oral motor control and 
had a score of 3 or higher on the Teacher Drooling Scale (a 5-point scale to 
express the clinical severity and frequency of drooling; 5=constantly wet and 
leaking saliva, 1=no drooling).15 None had undergone previous treatment with 
Botulinum Toxin type A or surgery for saliva control.
For the statistical analyses, the following classifications were used: the first to 
investigate the influence of three categories (spastic CP subtype, dyskinetic CP 
subtype, and mental disability not classified within the CP group), and secondly to 
explore the differences within the CP group (the two CP subtypes). All medications 
taken to treat drooling or to influence salivary secretion (especially benzodia­
zepines and neuroleptic drugs) were stopped at least three months before the start 
of the treatment. No limits were set concerning the use of antiepileptic drugs and 
the child’s level of cognitive development. Data from children diagnosed with ataxic 
CP subtype, Worster Drought Syndrome or a progressive neurological condition 
were excluded from the study. The research was conducted in accordance with 
national and international ethics standards, and the Regional Committee on 
Research Involving Human Subjects approved the study. Informed consent was 
obtained from the parents or caregivers of all children.
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An ultrasound-guided injection of Botulinum Toxin type A was injected bilaterally 
into the submandibular salivary glands divided over two sites per gland using a 
25 G needle (Spinocan®). A total dose of 50U Botox® (Allergan B.V., Nieuwegein, 
The Netherlands), diluted with 1.5 ml saline, was used. Drooling intensity and 
salivary flow were measured at baseline and at 8 weeks after injection. Drooling 
intensity was evaluated using the Drooling Quotient, a semi quantitative 
observational method (expressed as a percentage) representing the actual 
clinical appearance of saliva loss. The Drooling Quotient was scored according 
to the original design, drooling was evaluated during a 10-minute episode. A 
drooling episode was defined as new saliva present on the lip margin or dropping 
from the chin. The presence or absence of drooling was assessed every 15 
seconds (40 observations in 10 minutes).16
To measure the salivary flow rate we used the “swab method”: after the oral cavity 
had been dried with sterile gauze three absorbent dental cotton rolls (Salivette®; 
Sarstedt B.V., Etten-Leur, The Netherlands) were placed in the mouth for periods of 
5 minutes: one roll under the tongue directly in front of the orifices of the 
submandibular and sublingual glands, and two rolls in the upper vestibules at the 
openings of the parotid ducts.17 Two well-trained speech and language therapists 
conducted all the assessments which always took place in the morning, 1 hour 
after the last meal. The cotton rolls were weighed before and after the procedure 
using an electronic scale, which is sensitive to 0.01g. The roll under the tongue and 
the two upper vestibules-rolls were weighted separately to be defined as 
submandibular and parotid flow. The increase in weight during the 5-minute period 
was converted into milliliters of saliva per minute to determine salivary flow rate.
At each assessment the medical history was taken, especially regarding feeding, 
speech, coughing and salivary aspects.18 In addition, the parents were asked to 
register all possible side effects in a diary.
Data analysis
Baseline evaluation. Data analysis included descriptive statistics; the median 
salivary flow rates and the median Drooling Quotient. The median salivary flow 
rates and Drooling Quotient were compared between the three categories using 
non-parametric statistics (Kruskal-Wallis and Mann-Whitney-U Tests), because of
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non-normal distribution of these measures. Missing data were seldom, but on 
occasion adjusted by the overall mean of the group.
Therapy response. Multivariable analyses of variance (MANOVA) with a repeated 
measures structure were used to identify differences in mean submandibular and 
parotid flow, and Drooling Quotient across time using the baseline and 8 weeks 
assessment as variables. In addition, when either of the analyses had a significant 
effect, a post hoc test was performed to determine the differences between the 
groups. Since we wanted to control for the Type I error rate, Bonferroni adjustment 
for multiple comparison was used.
Therapy failure and clinical variables. A successful therapy response was 
defined as 30 percent submandibular flow reduction and/or 50 percent reduction 
of the Drooling Quotient. The 30% demand has been previously reported and is 
explained by the estimated measurement error of the swab method to evaluate 
the salivary flow rate.17 A 50% reduction in the Drooling Quotient reflected a clinical 
relevant change.7 The submandibular glands produce about 60 to 70% of baseline 
salivary flow. In the event the Drooling Quotient is reduced by 50% after Botulinum 
Toxin injections, the change of flow from the submandibular glands, being the 
only gland exposed to this intervention, must have added substantially to this 
reduction. All participants were categorized as responsive or as unresponsive to 
submandibular Botulinum Toxin type A. MANOVA with a repeated measures 
structure was used to identify differences in the mean parotid flow between the 
responding and the non-responding groups. In addition, for each group 
(responsive or unresponsive to Botulinum Toxin type A) we computed the 
Spearman’s correlation coefficient to define the magnitude of the associations 
between spastic or dyskinetic CP subtype, mental disability, mobility level and 
treatment response. For all statistics, the level of significance for two-tailed 
p-values was set at < 0.05. All statistical procedures were carried out using SSPS 
17.0 for Windows.
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Results
All children completed the treatment. See Table 1 for clinical characteristics. 
There was no significant difference in the baseline demographic variables 
between the groups, with the exception of mobility. The mobility level differed 
between the children with mental disability and the total CP group 
(U =196.00; p<0.001) and also between the children with spastic and dyskinetic 
CP subtype (U=1038.00;p = 0.02). Because of limitations related to the clinical 
diagnoses, it was not always possible to obtain simultaneous scores for the swab 
tests and the Drooling Quotient at one measurement session. The swab testing at 
baseline could be performed in 109 children and in 100 children at the 8 week 
assessment. At baseline the Drooling Quotient was determined in 120 children 
and at 8 weeks in 109 children. Missing data (14%) occurred at different 
assessment moments randomly spread over all children. Data of the median
Table 1 Clinical characteristics
5
All patients (n=126) Spastic CP Dyskinetic CP Mental disability without CP
62/126 (49%) 45/126 (36%) 19/126 (15%)
Affected side Quadriplegic 58 Bilateral affected Not applicable
Hemiplegic 4
Mean Age (SD) o)m5y(4
o
m41y y)(5
O
m2y0 11y (6y 4mo)
Sex (male/female) 43/19 27/18 11/8
DA
<4y 34 (55%) 22 (49%) 15 (79%)
4-6y;IQ<70 11 (18%) 9 (20%) 0 (0%)
4-6y;IQ>70 2 (3%) 1 (2%) 0 (0%)
>6y 15 (24%) 13 (29%) 4 (21%)
GMFCS*
I 0 (0%) 0 (0%) All ambulatory
II 6 (10%) 2 (4%)
III 21 (34%) 6 (13%)
IV 18 (29%) 19 (42%)
V 17 (27%) 18 (40%)
CP = Cerebral Palsy; SD = Standard Deviation 
DA = Developmental age
GMFCS = Gross Motor Functional Classification System 
*Kruskal-Wallis Test: significantly difference between the three groups
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submandibular and parotid flow rates, and Drooling Quotient at baseline and at 8 
weeks after injection of all participants are shown in Table 2. For the results 
between the diagnosis categories at baseline and after submandibular Botulinum 
Toxin type A therapy see Table 3.
Table 2 Median Drooling Quotient and salivary flow rate differences (range) in 
time between each group
Drooling parameters Spastic CP Dyskinetic CP Mental disability without CP
Sm0 ml/min 0.39 (0.08-0.68) 0.38 (0.06-1.09) 0.36 (0.16-0.48)
Par0 ml/min 0.32 (0.0-1.06) 0.36 (0.04-1.25) 0.24 (0.04-0.94)
DQ0 % 22.5 (0.0-80.0) 32.5 (0.0-97.5) 27.5 (0.0-77.5)
Sm8 ml/min 0.22 (0.02-0.85) 0.26 (0.04-0.48) 0.20 (0.04-0.8)
Par8 ml/min 0.27 (0.0-1.12) 0.27 (0.0-0.61) 0.22 (0.0-0.68)
DQ8 % 16.9 (0.0-65.0) 12.5 (0.0-57.5) 15.0 (0.0-27.5)
CP = Cerebral Palsy
Sm0, Par0 and DQ0 = median submandibular and parotid flow and Drooling Quotient at baseline 
Sm8, Par8, DQ8 = median submandibular and parotid flow and Drooling Quotient at the 8 weeks 
assessment
bold Mann Whitney U test = significant difference for median Drooling Quotient at baseline between 
children with spastic and with dyskinetic CP; p=0.03
Table 3 Results between the diagnosis categories
Patient groups Baseline Therapy response
Spastic vs. dyskinetic CP subtype DQ H(2)=4.96;p=0.08 )=3)2F( 8.00.=
aLO2.
vs. mental disability without CP Sm h (2)=0.46;p =0.79 )=3)2F( 5.60.=.40.
Par Hß)=0.58;p=0.75 )=3)2F( =4.67;p=0.01*
Spastic vs. dyskinetic CP subtype DQ U=1053.00; p=0.03 F(1;105)=5.01; p=0.03
Sm U=1343.00; p=0.74 f (1;105)=0.60;p =0.44
Par U=1274.00; p=0.44 F0;105)=8.97;p=0.01t
CP = Cerebral Palsy; Vs. = versus; DQ = Drooling Quotient; Sm = Submandibular flow 
Par = Parotid flow
* Post hoc Test = non-significant 
f Test of Between-Subjects effects = non-significant
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Therapy failure and clinical variables
According to our definition, 93 children were full responders and 33 children were 
unresponsive to Botulinum Toxin type A (see Table 4). At baseline there were 
neither statistically significant differences between the median submandibular 
flow rate (U=1189.50;p = 0.06) nor the median Drooling Quotient (U=1302.50; 
p = 0.20), whereas the difference for the median parotid flow rate was statistically 
significant (U=1099.00;p=0.02) between the children responsive or unresponsive 
to Botulinum Toxin type A. Furthermore, in the children responsive to Botulinum 
Toxin type A, decrease of submandibular flow rate across time was accompanied 
with decrease of parotid flow, whereas in children unresponsive to Botulinum Toxin 
type A the parotid flow rate increased marginally. The difference in the parotid flow
Table 4 Characteristics of the children whom are responsive or unresponsive to 
Botulinum Toxin type A
All patients (n=126) Responders (n=93) Non-responders (n=33)
Spastic CP* 44/62 (71%) 18/62 (29%)
Dyskinetic CP 35/45 (78%) 10/45 (22%)
Mental disability without CP 14/19 (74%) 5/19 (26%)
Mean age (SD) 11y 1mo (5y 6 mo) 10y 4mo (4y 8mo)
Sex (male/female) 61/32 20/13
DA<4y* 52 (56%) 19 (58%)
4-6y;IQ<70 18 (19%) 2 (6%)
4-6y;IQ>70 2 (2%) 1 (3%)
>6y 21 (23%) 11 (33%)
Sm0 ml/min (range) 0.42 (0.06-1.09) 0.34 (0.08-0.60)
Par0 ml/minf 0.38 (0.04-1.25) 0.20 (0.0-1.06)
DQ0 % 28.1 (0 .0-97.5) 22.5 (0 .0-80.0)
Sm8 ml/min (range) 0.18 (0 .02-0.54) 0.28 (0 .12-0 .85)
Par8 ml/min 0.27 (0.0-0.86) 0.27 (0 .04-1.12)
DQ8 % 12.5 (0 .0-57.5) 17.5 (2.5-65 .0)
SD = Standard Deviation, y=  year , mo=month, DA = developmental age 
Sm0, Par0 and DQ0 = median submandibular and parotid flow and Drooling Quotient at baseline 
Sm8, Par8 and DQ8 = median submandibular and parotid flow and Drooling Quotient at the 8 weeks 
assessment point
* Spearman's correlation coefficients = non-signifiant 
t p=0.02
5
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rates over time was statistically significant (F(1;124) = 20.92;p<0.001) between 
the responders and non responders. The median parotid flow rates across time 
between children responsive and unresponsive to Botulinum Toxin type A are 
presented in Figure 1. Clinical variables as Developmental Age (rs=-0.03;p=0.71), 
mobility level (rs=0.08;p = 0.38) and spastic or dyskinetic CP (rs=0.08;p = 0.43) 
did not significantly correlate with response percentage.
Although injections were usually well tolerated, there were several minor side 
effects in this series (see Table 5).
Figure 1 Median parotid flow rate in time between children responsive and 
unresponsive to Botulinum Toxin type A
= responsive to BoNT-A (n=97)
= unresponsive to BoNT-A (n=33)
X-axis = assessment points; 1 = at baseline, 2 = at 8 weeks after injection 
Y-axis = median parotid flow rate (ml/min)
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Table 5 Side-effects after Botulinum Toxin type A at the 8 weeks assessment
Spastic CP 
(n=62)
Dyskinetic CP (n=45) Mental disability without CP 
(n=19)
R NR R NR R NR
Increased salivary viscosity 9/62 (15%) 2/62 (3%) 16/45 (36%) 3/45 (6%) 1/19(5%; 0/19 (0%)
Reduced salivary viscosity 1/62 (2%) 0/62 (0%) 1/45 (2%) 0/45 (0%) 0/19 (0%) 0/19 (o%;
Problemful swallowing 2/62 (3%) 2/62 (3%) 2/45 (4%) 0/45 (0%) 0/19 (0%) 2/19 (77%)
Raised frequency of pulmonary infections 3/62 (5%) 2/62 (3%) 1/45 (2%) 0/45 (0%) 0/19 (0%) 0/19 (0%)
Speech problems 1/62 (2%) 1/62 (2%) 0/45 (0%) 0/45 (0%) 0/19 (0%) 0/19 (0%)
Dry mouth 0/62 (0%) 0/62 (0%) 1/45 (2%) 1/45 (2%) 0/19 (0%) 0/19 (0%)
Oral odour 0/62 (0%) 0/62 (0%) 0/45 (0%) 0/45 (0%) 1/19(5%J 0/19 (0%)
CP = Cerebral Palsy
R = responder to Botulinum Toxin type A
NR = non-responder to Botulinum Toxin type A
number of patients with side effects / total number of patients
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Discussion
This prospective study suggests that submandibular Botulinum Toxin type A 
treatment for drooling has similar effects across severely affected children with 
spastic or dyskinetic CP, or those with mental disability without CP. The data did 
not support the phenomenon of increased salivary flow due to mechanical 
stimulation of salivary glands in dyskinetic CP, however the findings did suggest 
that drooling is clinically distinct between children with spastic and dyskinetic CP. 
Although increased salivary parotid flow rates in children unresponsive to 
submandibular Botulinum Toxin type A were found, the role of parotid flow in 
therapy failure could not be settled in the current study. Therapy failure might 
mainly be explained by factors that influence the intra oral management of saliva 
such as head position, lip closure and disturbed oral movements instead of 
biological factors such as neurological regulatory mechanisms of salivary flow. 
As generally discussed in CP literature, the rate of mental disability and 
dyskinesia increases as functionality decreases. Against this background, we 
concluded that our group represented not an average group of children with CP, 
but a very severely affected group.19,20
The overall percentage of responders (74%) was in accordance with a former 
study (70%).7,21 Criticizers could argue that an overestimation of the effect due 
to the used imputation method is possible. Nevertheless, the mean imputation 
method provided unbiased estimates in current study, because the missing 
values met the strong assumption of being missing completely ad random.22 
Earlier it was suggested that in those children with dyskinetic disorders drooling 
might be caused by increased production of saliva due to constantly stimulation 
of the parotid glands. In the present study we were unable to demonstrate this. 
A possible explanation for this could be that the swab method technique itself 
plays a role. The position of the cottons rolls limited movements of the jaw 
and tongue considerably (“fixed mouth”), hindering potential salivary gland 
stimulation in children with dyskinetic CP during the assessments. The increased 
drooling intensity in dyskinetic CP assessed by the Drooling Quotient 
observation, where voluntary oral motor function was still possible (“dynamic 
mouth”), suggested that mechanical stimulation of the salivary glands might 
contribute to drooling in the dyskinetic CP subtype. Furthermore, the children 
with dyskinetic CP seemed to have better residual swallowing functions
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explained by the clear decrease of the Drooling Quotient after submandibular 
Botulinum application.
The clinical response failure was approximately 26% in our study. Since ultrasound 
was used, incorrect application of Botulinum Toxin type A would not be likely as a 
reason for the observed therapy failure. Besides, adequate doses were used and 
response failure due to antibody formation to the first Botulinum Toxin type A 
application can be considered to be irrelevant. Moreover, it was very unlikely that 
chemical diffusion of the Toxin via local vasculature or by gravity influence caused 
the parotid flow to decrease as none of the participants had complaints of bulbar 
muscle weakness.23
One possible explanation for the observed therapy failure might be the inadequate 
inhibition of the reflex arc of salivary secretion after Botulinum Toxin application. 
Saliva secretion is a nerve mediated reflex, and once the autonomic nerve in 
particular the parasympathetic nerve supply, has been interrupted secretion from 
almost all salivary glands will entirely cease.24 It is understood that under normal 
conditions inhibition of reflex salivary secretion is centrally controlled. However, 
under non-physiological conditions, for instance after Botulinum Toxin application, 
peripheral sympathetic inhibition of salivary secretion comes into action.8 It might 
be possible that the concept of insufficient peripheral sympathetic inhibition of 
the salivary secretion did play a role in unresponsiveness to Botulinum Toxin. 
Another explanation for response failure may be the contribution of factors related 
to handling of saliva. An earlier study showed that the response rate cannot be 
improved by simply injecting the submandibular and parotid glands concurrently.25 
Moreover, in the present study it was observed that the response to submandibular 
Botulinum Toxin type A changes according to the definition of good clinical 
response. As the definition of response was defined as a 30 percent submandibular 
flow reduction (“biological factor”), the size of the effect decreased from 76% to 
65% and even to 47% if response was defined as a 50 percent reduction of 
Drooling Quotient (linked to the ability to control saliva). Therefore, it might well be 
that “factors related to handling of saliva” even more than “biological factors” 
contribute to therapy failure.
Until now we are unable to predict who will respond to Botulinum Toxin type A. 
Moreover, univariate parameters such as motor impairment (“quality of 
movement”), mobility level and mental ability (“functional ability”), or even 
baseline Drooling Quotient and flow rates had no decisive value to discriminate
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between successful or unsuccessful therapy response in this study. Remarkably, 
before injection an important difference in the parotid flow rates was found 
between the children responsive and unresponsive to Botulinum Toxin type A 
(see Figure 1), however we were not able to explain the pathophysiology of the 
difference.
A disadvantage of present study might be the omission to measure the cares’ 
perception as ultimate test of treatment effectiveness.26 27 However, we specially 
wanted to focus on factors that might affect the saliva-control-intervention rather 
to evaluate the overall effectiveness of the intervention.
In conclusion, there were arguments for increased salivary flow due to hyperkinetic 
oral movements in dyskinetic CP and probably the children with dyskinetic CP 
might have better residual swallowing functions. However, the efficacy of 
submandibular Botulinum Toxin type A to treat drooling in children with CP 
subtypes or with mental disability without CP appeared to be similar. Future 
research is needed to provide tools to predict who will be a responder and to 
settle the contribution of parotid flow in response failure.
Acknowledgements
The work was supported by a grant from the Johanna Kinder Fonds (Arnhem, 
The Netherlands), a fund raising consortium in the field of child rehabilitation. 
The authors gratefully thank all children and their parents for their participation in 
this study, and Mrs. Patsy Anderson and Mrs. Stella De Bode for the valuable 
comments on the manuscript.
74
DOES MOTOR PERFORMANCE MATTER iN BOTULiNUM EFFiCACY FOR DROOLiNG?
Reference List
(1) Crysdale WS, White A. Submandibular duct (13) 
relocation for drooling: a 10-year experience
with 194 patients. Otolaryngol Head Neck Surg. 
1989;101(1):87-92.
(2) Erasmus CE, van Hulst K, Rotteveel LJ et al. 
Drooling in cerebral palsy: hypersalivation or (14) 
dysfunctional oral motor control? Dev Med Child 
Neurol. 2009;51(6):454-9.
(3) Tahmassebi JF, Curzon ME. The cause of 
drooling in children with cerebral palsy -- hyper- (15) 
salivation or swallowing defect? Int J Paediatr 
Dent. 2003; 13(2):106-111.
(4) Lespargot A, Langevin MF, Muller S, Guillemont (16) 
S. Swallowing disturbances associated with 
drooling in cerebral-palsied children. Dev Med (17) 
Child Neurol. 1993;35(4):298-304.
(5) Van de Heyning PH, Marquet JF, Creten WL. 
Drooling in children with cerebral palsy. Acta 
Otorhinolaryngol Belg. 1980;34(6):691-705. (18)
(6) Parkes J, Hill N, Platt MJ, Donnelly C. Oromotor 
dysfunction and communication impairments in 
children with cerebral palsy: a register study.
Dev Med Child Neurol. 2010;52(12):1113-9.
(7) Jongerius PH, van den Hoogen FJ, van Limbeek J, 
Gabreels FJ, van Hulst K, Rotteveel JJ. Effect of (19) 
botulinum toxin in the treatment of drooling: a 
controlled clinical trial. Pediatrics. 2004;114(3):620-
627.
(8) Garrett JR. The proper role of nerves in salivary (20) 
secretion: a review. J Dent Res. 1987;66(2):387-397.
(9) Erasmus CE, van Hulst K, van den Hoogen FJ et 
al. Thickened saliva after effective management
of drooling with botulinum toxin A. Dev Med (21) 
Child Neurol. 2010;52(6):e114-e118.
(10) Scheffer AR, Erasmus C, van Hulst K, van Limbeek 
J, Jongerius PH, van den Hoogen FJ. Efficacy and 
duration of botulinum toxin treatment for drooling in
131 children. Arch Otolaryngol Head Neck Surg. (22) 
2010;136(9):873-877.
(11) van der Burg JJ, Jongerius PH, van Limbeek J, 
van Hulst K, Rotteveel JJ. Social interaction and 
self-esteem of children with cerebral palsy after (23) 
treatment for severe drooling. Eur J Pediatr. 
2005;165:37-41.
(12) Palisano R, Rosenbaum P, Walter S, Russell D,
Wood E, Galuppi B. Development and reliability
of a system to classify gross motor function in (24) 
children with cerebral palsy. Dev Med Child 
Neurol. 1997;39(4):214-223.
McCormick A, Brien M, Plourde J, Wood E, 
Rosenbaum P, McLean J. Stability of the Gross 
Motor Function Classification System in adults 
with cerebral palsy. Dev Med Child Neurol. 
2007;49(4):265-269.
Bax M, Goldstein M, Rosenbaum P et al. 
Proposed definition and classification of 
cerebral palsy, April 2005. Dev Med Child 
Neurol. 2005;47(8):571-576.
Thomas-Stonell N , Greenberg J. Three treatment 
approaches and clinical factors in the reduction 
of drooling. Dysphagia. 1988;3(2):73-78.
Rapp D. Drool control: long-term follow-up. Dev 
Med Child Neurol. 1980;22(4):448-453. 
Jongerius PH, van Limbeek J, Rotteveel JJ. 
Assessment of salivary flow rate: biologic 
variation and measure error. Laryngoscope. 
2004;114(10):1801-1804. 
van der Burg JJ, Jongerius P, van Limbeek J, van 
Hulst K, Rotteveel J. Drooling in children with 
cerebral palsy: a qualitative method to evaluate 
parental perceptions of its impact on daily life, 
social interaction, and self-esteem. Int J Rehabil 
Res. 2006;29(2):179-182.
Shevell MI, Dagenais L, Hall N. Comorbidities in 
cerebral palsy and their relationship to 
neurologic subtype and GMFCS level. 
Neurology. 2009;72(24):2090-2096. 
Himmelmann K, Beckung E, Hagberg G, 
Uvebrant P. Gross and fine motor function and 
accompanying impairments in cerebral palsy. 
Dev Med Child Neurol. 2006;48(6):417-423. 
Jongerius PH, Rotteveel JJ, van Limbeek J, 
Gabreels FJ, van Hulst K, van den Hoogen FJ. 
Botulinum toxin effect on salivary flow rate in 
children with cerebral palsy. Neurology. 
2004;63(8):1371-1375.
Donders AR, van der Heijden GJ, Stijnen T, 
Moons KG. Review: a gentle introduction to 
imputation of missing values. J Clin Epidemiol. 
2006;59(10):1087-1091.
Meijer JW, van Kuijk AA, Geurts AC, Schelhaas 
HJ, Zwarts MJ. Acute deterioration of bulbar 
function after botulinum toxin treatment for 
sialorrhoea in amyotrophic lateral sclerosis. Am 
J Phys Med Rehabil. 2008;87(4):321-324.
Proctor GB, Carpenter GH. Regulation of 
salivary gland function by autonomic nerves. 
Auton Neurosci. 2007;133(1):3-18.
75
cHApTER 5
(25) Wilken B, Aslami B, Backes H. Successful 
treatment of drooling in children with neurological 
disorders with botulinum toxin A or B. Neurope­
diatrics. 2008;39(4):200-204.
(26) van der Burg JJ, Jongerius PH, van Hulst K, van 
Limbeek J, Rotteveel JJ. Drooling in children 
with cerebral palsy: effect of salivary flow 
reduction on daily life and care. Dev Med Child 
Neurol. 2006;48(2):103-107.
(27) Reid SM, Johnson HM, Reddihough DS. The 
Drooling Impact Scale: a measure of the impact 
of drooling in children with developmental 
disabilities. Dev Med Child Neurol. 2010;52(2): 
e23-e28.
76
DOES MOTOR PERFORMANCE MATTER iN BOTULiNUM EFFiCACY FOR DROOLiNG?
5
77

Chapter
What could predict effectiveness of Botulinum Toxin 
to treat drooling: 
A search for evidence of discriminatory factors on the 
level of body functions or structures
CE Erasmus MD1, K van Hulst MSc2, ART Scheffer MD3,
J van Limbeek MD PhD4, FJA van den Hoogen MD PhD3, JJ Rotteveel MD PhD1, 
PH Jongerius MD PhD5
1 Radboud University Nijmegen Medical Centre, Department of Paediatric Neurology, The Netherlands
2 Radboud University Nijmegen Medical Centre, Department of Rehabilitation, The Netherlands,
3 Radboud University Nijmegen Medical Centre, Department of Otorhinolaryngology, Head en Neck 
Surgery, The Netherlands
4 Sint Maartenskliniek, Department of Research, Development and Education, Nijmegen, The Netherlands
5 Sint Maartenskliniek, Department of Rehabilitation, The Netherlands
Accepted for publication in Eur J Paediatr Neurol
CHAPTER 6
Abstract
Background: The treatment of drooling is important to families that experience 
the daily impact and research to elucidate clinical factors that play a role in the 
outcome of drooling treatment should be encouraged.
Aim: To define clinical factors that influence therapy outcome of submandibular 
Botulinum Toxin (BoNT-A) injections for drooling.
Methods: Prospectively collected data of 128 children with cerebral palsy were 
evaluated; 80 spastic and 48 dyskinetic movement disorder, mostly Gross Motor 
Function Classification System III and higher; over 70% had an IQ < 70. In addition, 
23 fully ambulant children with exclusively intellectual disability were treated for 
drooling by ultrasound-guided injections of BoNT-A into the submandibular glands. 
Salivary flow rates and drooling quotients were measured at baseline and at 8 
weeks after injection. Extensive information about the oral motor performance was 
gathered. Successful clinical response was defined as a 50 % reduction of the 
baseline Drooling Quotient; 85 children were responsive to BoNT-A and 66 children 
unresponsive.
Results: Five nominated clinical factors that possibly could influence saliva 
reduction (head position, lip seal, voluntary control over the tongue, control of 
voluntary movement functions, and mental age) did not influence the 
responsiveness to BoNT-A.
Interpretation: Other variables need to be considered to predict the outcome of 
BoNT-A treatment. This article describes the first attempt to reveal the contribution 
of body functions and structures to the outcome of BoNT-A submandibular 
injections.
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Introduction
Earlier drooling treatment results showed that up to 30 % of patients did not 
respond to submandibular injection of Botulinum Toxin Type A (BoNT-A) if 
response was defined as a 30% reduction of submandibular salivary flow in 
combination with a 50% reduction of the Drooling Quotient (DQ).1,2 Given the 
number of non-responders, further research necessitates to search for factors 
that cause therapy failure.
BoNT-A injections result in a substantial direct effect on submandibular flow (SF) 
and have an indirect effect on the saliva regulatory mechanisms. Hence, the 
therapy effect of submandibular BoNT-A injections might be influenced on the 
one hand by pharmacological properties (type of Botulinum Toxin, dilution, 
injected dosage, secondary antibody response, and pharmacokinetics in relation 
to brand) and on the other hand by clinical variables (e.g. gross motor functions, 
cerebral palsy (CP) subtype, oral motor functions, mental ability). The primary 
purpose of the present cohort study was to reveal body functions and structures 
(as defined by the International Classification of Functioning, Disability and Health 
for Children and Youth (ICF-CY)) that could influence therapy outcome.
The majority of individuals with CP produce normal amounts of saliva, and it is 
generally accepted that the amount of saliva is not the decisive factor responsible for 
drooling in children with CP.3 In the absence of evidence, researchers thus far have 
suggested a positive contribution to drooling severity of poor head control, 
dysfunctional oralmotor control, a decreased swallow frequency, reduced intra-oral 
suction, dysarthria severity, and a degree of malocclusion in children with CP.4-8 No 
correlation has been found between mobility level and the amount of saliva drooled.5 
Yet, little is known about clinical factors in relation to treatment outcome of 
submandibular gland BoNT-A application to treat drooling. Controlled data are not 
available, and it is unclear why some children with CP or developmental delay who 
drool respond well to BoNT-A while others only respond to a lesser extent. To date 
only a few population studies focusing on behavior modification therapy for drooling 
reduction have included clinical factors. It has been shown that saliva control and 
consequently drooling severity is most positively associated with age and the ability 
to swallow, control the head, and walk without aid.9 Currently, there is no agreement 
about what child characteristics will distinguish between a “successful” or 
“unsuccessful” therapy response after submandibular BoNT-A injections.
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This article describes the first attempt to reveal the contribution of body functions 
and structures to the outcome of BoNT-A submandibular injections to treat 
drooling. Body function and structure items, assumed as relevant clinical factors 
that might contribute to the treatment outcome are listed in Table 1. Given the 
costs of BoNT-A and the fact that anesthesia is needed, it is important to know 
what factors might influence treatment outcome of BoNT-A injections and to 
formulate strict indications for this therapy.
Table 1 Definition of the Clinical Factors
Variables Definition
Head Position Ante flexion vs. lateral flexion-retro flexion-normal
Tongue protrusion Permanently-often vs. sometimes-never
Lip seal in daily activity Impossible-clearly different vs. slightly divergent-normal
Voluntary tongue control No-almost never vs. sometimes-normal
Developmental Age < 4 years and 4-6 years with IQ < 70 vs. 4-6 years with 
IQ > 70 and > 6 years
Control of voluntary 
movement functions
GMFCS I-III (ambulatory) vs. IV-V (non-ambulatory)
TOM-Dysarthria Very serious-serious vs. moderate-mild-no dysarthria
DSS-Dysphagia Very serious-serious vs. moderate-mild-minimal-no 
dysphagia
vs. = versus.
GMFCS = Gross Motor Classification Function System: I = performing gross motor skills including 
running and jumping but reduced speed, balance, and coordination, V = no means of independent 
mobility
TOM = Therapy Outcome Measure (Dutch and modified version of the subscales for dysarthria) 
DSS = Dysphagia Disorder Survey (Dutch version)
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Method
Participants. Prospectively collected data from 151 children (mean age 10 years 10 
months, SD 4 years 10 months) screened in the outpatient drooling clinic at 
the Radboud University Nijmegen Medical Centre, The Netherlands between 
February 2000 and March 2010 were evaluated. The children were categorized 
as having CP or intellectual disability based upon Developmental Age (DA).10 
The children with CP were classified according to the predominant motor type.11 The 
severity of motor disturbances was assessed by the Gross Motor Function 
Classification System (GMFCS).12 Most of the children with CP had a mobility score of 
III or higher on the GMFCS; more than 70% had an Intelligence Quotient (IQ) below 
70. All children with intellectual disabilities were ambulant, and had an IQ below 70. 
Inclusion criteria were a score of 3 or higher on the Teacher Drooling Scale (a 
5-point scale to express the clinical severity and frequency of drooling; 
5 = constantly wet and leaking saliva, 1 = no drooling).9 None of the participants 
had undergone previous BoNT-A therapy or surgical procedures for saliva control. 
All medications to control drooling or influencing salivary secretion were stopped 
at least 3 months before the start of the study. This research was conducted in 
accordance with national and international ethical standards. The Regional 
Committee on Research Involving Human Subjects approved the study. Informed 
consent was obtained from the parents or caregivers of all children.
Exclusion. No limits were set with regard to the child’s level of cognitive 
development. Children with an ataxic CP subtype, or the Worster-Drought 
Syndrome as well as children with a progressive neurological condition were 
excluded from the study.
Procedures. A single ultrasound-guided injection of BoNT-A was given bilaterally 
into the submandibular salivary glands. A total dose of 50U Botox® (Allergan B.V., 
Nieuwegein, The Netherlands) was used. During a rest situation when a person 
does not eat or drink the submandibular glands produces approximately 60 - 
70% of the whole amount of saliva. The activity of the parotid glands, being 
anatomically the largest glands, increases during gustatory stimulation, a function 
with which we did not want to interfere.
Scoring. All children were evaluated after the first injection for the drooling 
quotient, the salivary flow as well as for clinical factors. Those were assessed at 
baseline and 8 weeks after injection.
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After completing a thorough literature study, we identified that the following 
factors are suggested to contribute to drooling severity: head position, lip seal, 
voluntary control of tongue movements, control of voluntary movement functions, 
and mental age (see Table 1). The described factors all are authors opinions and 
in this sense reflect ‘best practice’ being a low level of evidence. Nevertheless, it 
is postulated that these factors could explain the lack of response to BoNT-A 
drooling treatment because clinical arguments support this approach.
The drooling quotient (DQ), a semi quantitative observational method (expressed 
as a percentage), was scored according to the original design by recording all 
episodes of drooling during 10 minutes. A drooling episode was defined as new 
saliva being present on the lip margin or dripping from the chin. The presence or 
absence of drooling was assessed every 15 seconds (40 observations in 10 
minutes).13 We postulate that the DQ more obvious represented clinical aspects, 
and in view of clinical relevance the DQ was used as the indicator of clinical 
effects. In general, the submandibular glands produce about 60 to 70% of 
baseline salivary flow. In the event the DQ is reduced by 50% after BoNT-A, the 
change of flow from the submandibular glands, being the only gland exposed to 
this intervention, must have added substantially to this reduction. Thus, a 50% 
reduction in the DQ reflected a clinical relevant change.114 Therefore a successful 
clinical response was defined as a 50% reduction of the DQ at the 8 weeks 
assessment in this study.
To measure the salivary flow rate, after drying the oral cavity with sterile gauze, 
three absorbent dental cotton rolls (Salivette®; Sarstedt B.V., Etten-Leur, The 
Netherlands) were placed in the oral cavity for a 5 minute-period: below the 
tongue in front of the orifices of the submandibular and sublingual glands as well 
as in the upper vestibules at the openings of the parotid ducts.
The morning and the 1-hour after the meal assessments were performed by a 
specially trained speech and language therapist (SLT). In addition, the SLT also 
gathered extensive information about the oral motor performance. The cotton 
rolls were weighed before and after the procedure using an electronic scale, 
which was sensitive to 0.01 g. The increase in weight over the 5-minute period 
was converted into milliliters of saliva per minute to determine salivary flow rate. 
The decrease of the salivary submandibular flow (SF) was only used to monitor 
the drooling control intervention.
The parotid flow (PF) profiles, for each of the three categories, spastic CP,
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dyskinetic CP and intellectual disability, were evaluated to indentify compensatory 
raised parotid flow after submandibular gland BoNT-A injections.
Dysarthria severity was scored using the Dutch and modified version of the 
subscales for dysarthria of the Therapy Outcome Measure (TOM).15 The Dutch 
version of the Dysphagia Disorder Survey (DDS) was used to assess the overall 
feeding and swallowing functions.16
Statistical analysis
Data analysis included the following descriptive statistics: the median salivary 
flow rates and median DQ. To identify differences in the median submandibular 
and parotid flows over time Wilcoxon Signed Rank Tests were used. The clinical 
factors related to therapy response were evaluated using chi-square statistics, 
and logistic regression analyses were used to predict therapeutic response. The 
Nagelkerke R2-statistic was used as an indicator of the variation explained by the 
model.
The missing data for the flow rates and DQs were adjusted by geometric mean 
substitution; the missing values of the clinical factors were substituted by hot-deck 
imputation (substitution with data from another observation of the same subject). 
For all statistics, the level of significance for one-tailed p-values was set at < 0.05. 
An exception was made for the chi-square testing; the level of the one-tailed 
p-values was set at < 0.2 or a significant difference was assumed if the relationship 
to therapy outcome could be considered as biologically plausible. All statistical 
procedures were carried out using SSPS 17.0 for Windows.
Results
All children completed the treatment. See Table 2 for clinical characteristics. The 
swab testing at baseline could be performed for 129/151 children and, for 131/151 
children at the 8-week assessment. At baseline the DQ was determined for 
147/151 children and at 8 weeks for 148/151 children. All missing data points for 
the flow rates and DQ occurred at different assessment points, in different 
children. The geometric mean for the variable was imputed for missing data.
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Table 2 Clinical Characteristics
Responders 
N=85 (56%)
Non-responders 
N=66 (44%)
Mean age 
(SD)
10y 8mo 
(4y 10mo)
10y 11mo 
(4y 11 mo)
Sex M/F 52/33 38/28
Diagnosis
• Spastic CP
• Dyskinetic CP
• Intellectual disability
40/80 (50%) 
34/48 (71%) 
11/23 (48%)
40/80 (50%) 
14/48 (29%) 
12/23 (52%)
Drooling Characteristics Pre Post Pre Post
• Median SF 0.40 0.18 0.41 0.24
(range) (0.0-2.10) (0 .02-0 .54 ) (0 .08 -0 .98 ) (0 .04-0 .85 )
• Median PF 0.34 0.27 0.33 0.33
(range) (0.04-4 .10) (0.0-1.02) (0.0-1.19) (0.0-1.18)
• Median DQ 32.5 2.5 24.7 25.0
(range) (0 .0-100.0) (0 .0 -40 .0 ) (0 .0 -80 .0 ) (2 .5 -68 .0 )
(SD) = Standard Deviation; Y = year, Mo = month; CP = Cerebral Palsy; SF = Submandibular Flow 
in ml/min; PF =Parotid Flow in ml/min; DQ = Drooling Quotient in %; Pre = Before Botulinum Toxin 
injection; Post = After Botulinum Toxin injection
According the definition of response, 56% of the children showed a good clinical 
response to submandibular BoNT-A as measured by the DQ (Table 2). This also 
means that a substantial proportion of the study populations did not meet the 
criterion of adequate clinical improvement, being a 50% reduction of the DQ. 
All children showed a statistically significant reduction in the SF whether their 
clinical drooling was responsive or unresponsive to submandibular BoNT-A 
injections (z = -7.60, p < 0.001 resp. z = -5.24, p < 0.001)).
Surprisingly, children with dyskinetic CP that showed a positive response to the 
treatment also showed a statistically significant decrease in PF (z = -2.49, p = 
0.01). This was not true for children with spastic CP type or exclusively mentally 
disabled children showing a positive response to drooling treatment. They had no 
statistically significant difference between the pre treatment and post treatment 
medians for the PF (z = -0.82, p = 0.41 resp. z = -0.82, p = 0.42).
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For the non-responders per diagnosis category there was no statistically 
significant reduction in PF over time (spastic CP (z = -0.46, p = 0.65); intellectual 
disability (z = -1.18, p = 0.24); dyskinetic CP (z = -0.46, p = 0.65)).
Although not found to be statistically significant in the univariate analysis, five 
factors (see table 3) are considered to be biologically plausible variables related 
to treatment outcome; they were analyzed by logistic regression. Note that the 
results from the logistic regression have been presented only to provide an 
indication of how much of the variability in the treatment could possibly be 
explained by a model containing just these five clinical variables. In addition, 
missing data per variable are given (Table 3).
Table 3 Factors contributing to therapy response
Variables Missing
dataa
Univariate
analysis
(p-value)
Head position 19/151 0.17
Lip seal in daily activity 2/151 0 .2 8
Voluntary tongue control 26/151 0 .3 2
DA 0/151 0 .2 8
Control of voluntary movement functions 0/151 0 .29
TOM-Dysarthria 5/151 0.47
DSS-Dysphagia 2/151 0.42
Tongue protrusion 8/151 0.42
Head position, Lip seal, Voluntary tongue control, 
DA and Movement functions if combined
Logistic
regression
R2 =0.27; p=0.18
The clinical factors showed no relation to therapy response in the univariate analysis as well as in 
logistic regression analyses. The Nagelkerke R2 should be between 0 and 1, with 0 denoting that 
model does not explain any variation and 1 denoting that it perfectly explains the observed variation. 
DA = Developmental Age
TOM = Therapy Outcome Measure (the Dutch and modified version of the subscales for dysarthria) 
DSS = Dutch version of the Dysphagia Disorder Survey 
a all randomly missing values adjusted by Hot-deck Imputation 
Bold (italic) = biological plausible factors
6
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Discussion
The purpose of this investigation was to determine factors, as derived from the 
ICF-CY body function and structure paragraph, relevant to treatment outcome of 
submandibular gland BoNT-A injections in children with CP or intellectual 
disability. The results from this cohort study demonstrated that the BoNT-A 
submandibular injections resulted in a statistically significant reduction in the 
saliva production from the submandibular glands. This significance of the 
submandibular flow reduction was not expressed in the primary treatment 
outcome as investigated by the drooling quotient (DQ). The SF was reduced 
regardless the fact whether the child was classified as a responder of a 
non-responder.
In the current study we choose the DQ as measure, because it reflects more 
obvious the clinical outcome and relevance of the drooling treatment. According 
to the chosen strict response definition, 56% of the children showed a positive 
clinical response to submandibular BoNT-A application as measured by the DQ. 
In previous studies the success rate was higher because a broader definition of 
response was taken.1,2 However, the response rate of about 50% is in accordance 
with a recent study of our group.17
As generally discussed in the literature, the predominant motor types for 
individuals with CP are spasticity (91%) and dyskinesia (4%).18 Our study group 
does not reflect an average population of CP since the selection of patients was 
mainly based on the severity of drooling introducing a specific kind of selection. 
Dyskinetic CP was represented with 32% and most of them had a GMFCS level of 
III and higher. As functionality decreases the percentage of children with dyskinetic 
CP will increase up to 75%.19 Against this background, we concluded that the 
raised percentage of dyskinetic CP from average 4% up to 32%, presented more 
functionally affected individuals in our study.
On the level of body function this study repeatedly confirmed that BoNT-A has a 
positive outcome on salivary flow reduction. In spite of careful investigation and 
statistical analysis, no evidence could be found that the five nominated clinical 
factors (head position, lip seal, voluntary control over the tongue, control of 
voluntary movement functions, and mental age) would influence the clinical 
outcome to BoNT-A as measured by the DQ. Given the large number of patients 
in our cohort and the adequate methodological and statistical approach, this is
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an important finding. When grouped together these factors cannot indicate or 
predict which of the children will be responders or non-responders with the 
chosen level of response. This is the first step to reveal the apparently complicated 
issue of body functions and structures playing a role in drooling and its treatment 
outcome. These observations imply that other variables need to be considered to 
predict the outcome of BoNT-A treatment.
The five investigated clinical factors seem logical to influence treatment outcome. 
For example head position and lip seal are influenced by gravity. The same 
reasoning also applies to movement functions which are clearly related to head 
position. Previous investigations demonstrated that tongue mobility strongly is 
correlated with drooling and drooling control.6 Therefore, it seems plausible that 
the ability to control the tongue is an important factor related to therapy outcome, 
following the factor quantity of saliva reduction. Although to date no correlation 
has been found between mental age and successful training for drooling control13, 
the risk of oromotor impairment is raised by any degree of intellectual impairment20 
and the relationship between mental age and therapy outcome might be expected. 
To what extent this might be of importance for occupational therapy setting, 
remains open for debate and cannot be answered by the present study design. 
While the cluster of clinical variables could not predict which children would be 
responders, the converse is also true. Children with one or more ‘negatively rated’ 
clinical factors still can have a positive clinical outcome. In view of the fact that not 
all injections are successful, it should be kept in mind that the local effectivity of 
BoNT-A is not the same as the effectiveness on the functional level. The 
discrepancy between observed local effect (ie decrease of flow) and the clinically 
reported “functional efficacy” (i.e. insufficient drooling control) remains to be 
proven.21 Therefore, we evaluated the relationship between reflex saliva secretion 
of the parotid gland and observed therapy outcome. After BoNT-A, the reflex 
salivary secretion from all glands will be peripheral sympathetic inhibited22 and 
the median PF was expected to fall. Indeed, in some children the median PF 
decreased whether they were responder or not. However, it is more interesting to 
note that some children were even able to increase the parotid saliva secretion 
(Figure 1). There is evidence that the Hypothalamic-Pituitary Axis activity is 
altered in children with neurological disabilities.23-25 We suggest that peripheral 
sympathetic inhibition causes a decrease of the salivary secretion of the parotid 
gland after BoNT-A in almost all children26, but it might well be that dysfunctional
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Figure 1 Median Parotid Flow (PF) in responders and non-responders
Median PF in responders
Median PF in non-responders
2
♦ Spastic CP 0,40 0,33
Dyskinetic CP 0,25 0,31
Mental disorder 0,35 0,23
X-axis = assessments; 1 = assessment at baseline, 2 = 8 weeks-assessment 
Y-axis = median parotid flow in ml/min 
CP = Cerebral Palsy
regulation by hypothalamic pathways explains why in some children the reduced 
submandibular salivary flow remains uncompensated by sufficient increase of PF. 
Thus the biological local effect (decreased submandibular flow) is answered 
(immediately) by an adaptive (peripheral) reaction. Moreover, we hypothesized 
that therapy outcome to submandibular BoNT-A could also be influenced by
90
w h a t  c o u l d  pREDiCT EFFEcW EN Ess oF Bo t u UN u M ToxiN  To TREAT DRooLiNG
compensatory strategies of the central circuitries responsible for saliva production. 
Presumably, such concepts about BoNT-A as discussed here in the light of 
drooling, may be applicable for other applications of BoNT-A.
The findings of this study should be considered in light of the following limitations. 
First, this study took place in a rather heterogeneous population. Secondly, a 
disadvantage of present study might be the omission to measure the perception 
of carers.27
In sum, the response to submandibular BoNT-A on the combination of the clinical 
variables, and treatment results were not influenced by head position, lip seal, 
voluntary control of tongue movements, control of voluntary movement functions, 
and mental age. Research to elucidate clinical factors that play a role in the 
outcome of drooling treatment should be encouraged. Prediction of treatment 
outcome is important because Botulinum Toxin administration is costly and has 
to be repeatedly applied, while needing anesthesia.
Future research is also needed to evaluate the neuropharmacological properties 
of BoNT-A and other drooling treatment regimes in relation to therapy outcome 
(e.g. additionally injection of the parotid gland, repeated BoNT-A applications, 
dose-finding studies). However, it has been reported that improvement of the 
response rate will not be achieved by dose adjustments, which is likely to induce 
more adverse effects.28 Different treatment strategies, such as combination of 
BoNT-A injections into the submandibular as well into the parotid glands had only 
slightly improved response rate.29
Finally, the potential influence of an altered Hypothalamic-Pituitary Axis activity in 
children with neurological disabilities and drooling should be investigated.
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CHAPTER 7
Abstract
Aim: To evaluate the rheological properties of saliva after submandibular BoNT-A 
injections.
Method: We enrolled fifteen children diagnosed with spastic (9) or dyskinetic (6) 
quadriplegic CP; GMFCS IV or V (age three to 17 years, 11 males and six females) 
and two children with intellectual disability (IQ<70) who experienced moderate to 
severe drooling. Salivary flow rate using cotton rolls and Drooling Quotient were 
measured at baseline and at different intervals after BoNT injections up to 24 
weeks. The mucin concentration was analysed before and after BoNT treatment. 
Results: The submandibular flow rate (baseline 0.38 ml/min; 24 weeks after 
injection 0.26 ml/min) as well as the Drooling Quotient (baseline 42.5%; 24 weeks 
28.80%) were substantially reduced with a concomitant increase in mucin 
concentration within eight weeks after BoNT application (from 0.612 to 1.830 mg/ 
ml). Parents observed thickened saliva in nine children. Swallowing and chewing 
were problematic in seven children. Two of these children needed treatment with 
mucolytics because of pooling of thickened saliva in the throat.
Interpretation: In making decisions about the use of BoNT-A, the risk of problems 
with masticatory and swallowing functions due to thickening of saliva after BoNT 
treatment should be taken into account.
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Introduction
Local injection of Botulinum Toxin (BoNT) into the salivary glands is used for 
treatment of drooling. BoNT causes a temporary inhibition of SNAP-25: the 
presynaptic acetylcholine-exocytotic synaptosomal-associated protein with a 
molecular weight of 25 kDa. As a result, the gland’s secretory (water) capacity is 
depressed. After BoNT injection, the basal saliva secretion is usually sufficient to 
moisten the oral cavity and to facilitate swallowing of food. Incidental side-effects 
have been reported, such as flu-like symptoms lasting for less than two days, 
swallowing difficulties, viscous saliva and dryness of the mouth, transient slight 
weakness of the masseter muscle or mouth openers, and rarely jaw dislocation 1-6. 
Human saliva serves multiple functions in the oral cavity, including moistening of 
food, facilitation of mastication and swallowing, and cleaning and lubrication of 
the oral mucosa 7. The seromucous sublingual, submandibular, and palatine 
glands secrete mucins which coat and protect the epithelial tissue of the oral 
cavity, and give the typical viscoelastic character to saliva. Salivary mucins are 
primarily wetting agents which play a role in lubricating the tissue-environmental 
interface to produce low friction 89.
We observed that the saliva became sticky in some children after intraglandular 
botulinum application and assumed that sticky saliva may cause swallowing 
problems due to increased protein concentrations and changed salivary viscosity 
causing more friction 10. Previous studies focused on the effect of BoNT on 
salivary proteins such as secretory immunoglobulin A (immune system) and 
amylase (digestion), but salivary mucins, responsible for the rheological 
properties of saliva, have not been studied before 1112.
In view of the anticholinergic properties of BoNT, it is likely that the watery 
component of saliva will be reduced and that the concentration of mucins will 
increase post-BoNT injection. The present study was undertaken to investigate 
the viscoelasticity of saliva after BoNT application and to evaluate the 
consequences of changed viscoelasticity. Increased friction due to less effective 
wetting properties of saliva after BoNT application may cause intraoral discomfort 
and less effective mastication and swallowing.
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Method
Seventeen children (age three to 17 years, 11 males and six females) who were 
screened in the outpatient drooling clinic at the Radboud University Nijmegen 
Medical Centre, The Netherlands between 2000 and 2001 were enrolled in this 
study. Fifteen children were diagnosed with spastic (9) or dyskinetic (6) CP. They 
were bilaterally affected and were wheelchair bound with a Gross Motor Function 
Classification Scale IV or V. They had no oral speech and demonstrated moderate 
to severe dysfunctional oral motor control. Two children (one 12-year-old boy and 
one seven-year-old girl) with intellectual disability (developmental age < four 
years) were also included. These two children were ambulant without aids, but 
were unable to speak. All 17 children were fed orally and had a score of three or 
higher on the Teacher Drooling Scale (a 5-point scale to express the clinical 
severity and frequency of drooling; 5 = constantly wet and leaking saliva, 1 = no 
drooling) 13. None had previous surgical procedures for saliva control. All 
medications taken to treat drooling or influencing salivary secretion were stopped 
at least three months before start of the study. No limits were set with regard to 
the child’s level of mental development. The research was conducted in 
accordance with the national and international ethical standards and the Regional 
Committee on Research Involving Human Subjects approved the study. Written 
informed consent was obtained from the parents or caregivers of all children.
An ultra-sound-guided injection with Botulinum Toxin A was given bilaterally into 
the submandibular glands. A total dose of 30 U up to 50 U of Botox® (Allergan 
B.V., Nieuwegein, The Netherlands) was used. The drooling intensity and the 
salivary flow were measured at baseline and at two, four, eight, 16 and 24 weeks 
after injection. A least two mucin activity measurements within eight weeks after 
treatment with BoNT-A were required for inclusion in this study. At each 
assessment point, comprehensive details were collected about the child’s 
drooling, feeding, speech, presence or absence of coughing, and characteristics 
of saliva14. In addition, the parents were asked to register all possible side effects 
in a diary. Cervical auscultation was performed to look for pooling of secretions 
in the throat. The drooling intensity was evaluated with the Drooling Quotient 
(DQ), a semi-quantitative observational method (expressed as a percentage). 
The DQ was scored according to its original design during two periods of 10 
minutes separated by a 60-minute break. An episode of drooling was defined as
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new saliva present on the lip margin or drooling from the chin. Every 15 seconds 
(40 observations in 10 minutes) the presence or absence of drooling was 
assessed 15 To measure the salivary flow rate, absorbent dental cotton rolls 
(Salivette®; Sarstedt B.V., Etten-Leur, The Netherlands) were placed directly in 
front of the orifices of the submandibular and sublingular glands for five-minute 
intervals after drying the oral cavity with a sterile gauze. The assessments were 
conducted by the same speech language therapist, always in the morning, and 
one hour after the last meal 16. The cotton rolls were weighed before and after the 
procedure using an electronic scale, which was sensitive to 0.01 g. The increase 
in weight during the five-minute interval was converted into ml saliva/min.
After weighing, the cotton rolls were centrifuged and the saliva samples were 
stored at -20°. The total mucin concentration (U/ml) in thawed saliva was analysed 
using ELISA with mAb F2 as described previously 17. Briefly, isolated mucins were 
2-fold serially diluted in 0.1 M NaHCO3 (pH 9.6) starting from 2 ug/ml and incubated 
overnight at 4°C in polystyrene wells of microtiter plates. After rinsing, mAb F2 
(approximately 1 ug/ml) was added and the samples were incubated for one hour 
at 37°C. Bound antibodies were probed with peroxidase conjugated to rabbit 
anti-mouse immunoglobulin (Dakopatts, A/S, Glostrup, Denmark), using o-phe- 
nylene-diamine (0.4 mg/ml) and H2O2 (0.012 %) as substrates. Color development 
was measured at 490 ran with a Dynatech MR7000 microtiter plate reader 
(Dynatech Laboratories Ltd., Billinghurst, UK).
Statistical Analysis
Data analysis included descriptive statistics; the median submandibular flow 
rates, the median DQs, and the largest salivary flow and DQ reduction were 
calculated. Unwanted effects and side-effects were tabulated at subsequent 
measurement moments. Nonparametric Wilcoxon signed-ranks tests were done 
for submandibular flow as well as for DQ to analyze differences in flow rate and 
DQ. According to our definition, two mucin activity measurements within eight 
weeks after BoNT-A injection were required. Missing mucin data were adjusted by 
“last observation carried forward” (LOCF) in which the last valid measurement 
was taken to replace a missing value or by a “worst case scenario” (WCS) in 
which the baseline measurement replaced the missing value. In addition,
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multivariable analyses of variance (MANOVA) with a repeated measures structure 
were used to identify patterns of mucin response using the assessment points at 
two, four, and eight weeks as variables. For all statistics, a level of significance 
with one tailed p-values < 0.05 was mandatory. All statistical procedures were 
carried out using SSPS 16.0 for Windows.
Results
All children were included in the analysis, as none of them dropped out. In all 17 
children, we were able to measure the salivary flow rates and DQs at all 
assessment points. At baseline, data on mucin concentration were derived for all 
17 children as well. The mucin concentration could also be calculated for 13 
children at two weeks, for 12 children at 4 weeks, and for 14 children at eight 
weeks. The missing values occurred at different assessment points in different 
children. After treatment with BoNT, the median salivary flow rates and the median 
DQs were substantially reduced. Figure 1 shows the data of the median salivary 
flow rate and the DQ at consecutive assessment points. Eight weeks after BoNT 
application, a 50 percent reduction was seen in the median flow rate. Table 1
Figure 1 Median submandibular flow and DQ over time (N=17)
X-axis = assessment points over time; Y-axis = median submandibular flow on a logarithmic scale; 
DQ = Drooling Quotient; BL = baseline; BoNTx = Assessment points at x weeks after BoNT;
= Drooling Quotient; = flow
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shows the median of the flow and DQ over time. Compared to baseline, the 
median flow rates showed significant differences at all subsequent assessment 
points up to 16 weeks post BoNT application, except for the difference at four 
weeks post BoNT, which did not reach statistical significance. In addition, the 
median of the DQ measured at two, four, eight and 24 weeks also showed 
statistically significant differences compared to baseline. The parents noticed 
thickened saliva in nine children in the first eight weeks after BoNT application.
Table 1 Median flow rates and DQs between baseline and follow-up 
measurements
Flow rate (range) 
(ml/min)
Sign3 DQ (range) 
(%)
Sign3
BL 0.38
(from 0.10 to 0.68)
42.5
(from 6.25 to 81.25)
BoNT2 0.22
(from 0.04 to 0.66)
0.017 15,0
(from 0.0 to 65.0)
0 .003
BoNT4 0.20
(from 0.06 to 0.96)
0.068 18.80
(from 0.0 to 62.50)
0 .009
BoNT8 0.18
(from 0.04 to 0.54)
0.001 18.75
(from 1.30 to 58.75)
0 .007
BoNT16 0.26
(from 0.04 to 0.46)
0.002 25.0
(from 0.0 to 65.0)
0.118
BoNT24 0.26
(from 0.08 to 1.46)
0.132 28.80
(from 0.0 to 81.25)
0 .036
BL = baseline; BoNT= Botulinum Toxin; BoNTx = assessment points at x weeks after BoNT; DQ = 
Drooling Quotient; Sign = statistically significant different.
a non parametric two related samples test (Wilcoxon), two-sided p<0.05; Italico = statistically 
significant different.
Swallowing and chewing were problematic in seven children, and two of these 
children, who had never been diagnosed with respiratory diseases needed 
treatment with mucolytics because of frequent coughing due to pooling of 
thickened saliva in the throat. Three children had swallowing problems within two
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weeks after BoNT-A application and one child within one week. Another child had 
a dry mouth at night with an unpleasant oral odour. None of the parents mentioned 
any viscoelasticity problems at 16 and 24 weeks after BoNT injections (table 2).
Table 2 Results: side-effects
Number 
of patients
Thickening of saliva 
after BoNT-A injections
Swallowing/ 
chewing problems
Pooling of 
thickened saliva
Oral
Odour
1 Within 8 weeks + -
2 - - -
3 Within 8 weeks + -
4 - - -
5 Within 8 weeks + -
6 Within 1 week + +
7 - - -
8 Within 2 weeks + -
9 Within 2 weeks + +
10 - - -
11 - - -
12 Within 8 weeks + - +
13 - - -
14 - - -
15 - - -
16 Within 8 weeks - -
17 Within 2 weeks - -
BoNT = Botulinum Toxin; + = problems; - = no problems.
The individual salivary mucin concentrations differed between the children. Some 
children produced a small volume of highly viscous and sticky saliva which 
virtually completely remained absorbed onto the cotton rolls and could not be 
recovered for analysis. The values for the missing saliva samples (approximately 
20% randomly missing) were substituted as mentioned above. A MANOVA with a 
repeated measures structure was performed to evaluate mucin concentrations 
over time. Using the LOCF scenario, significant changes in mucin concentrations 
over time were seen in the multivariable procedure (Pillais Trace F=6 .552; df(3;14);
102
THICKENED SALiVA AFTER EFFECTiVE MANAGEMENT OF DROOLiNG WiTH BOTULiNUM TOXiN A
p = 0.005/2). Huynh-Feldt adaptation was used to correct the degrees of freedom. 
The within subjects factor (mucin concentration) showed a trend indicating that 
the mucin concentration increased over time (F=6.677; df(1.4;22.2); p = 0.01/2). 
Using the WCS, marginally significant changes in mucin concentrations over time 
were seen in the multivariable procedure (Pillais Trace F=2.492; df(3;14); 
p = 0.103/2). This might imply that no effect over time in increase of mucin 
concentration could be shown. Inspection of the graphical representation and the 
Standard Deviations (SD) made clear that the variance in the measurements at 
two weeks post BoNT had increased (SD=2.562) compared to the variance in the 
baseline observation (SD=1.025). The mucin concentrations at four and eight 
weeks post BoNT remained constant on a higher level compared to baseline and 
their variances remained in the same range (SD = 1.383 and 1.536, respectively). 
Therefore, it may be concluded that the results from the WCS (F=2.597; df(3;48); 
p = 0.063/2) coincided with the results from the LOCF analysis, indicating that the 
mean mucin concentration increased after BoNT treatment (figure 2).
Figure 2 Mean mucin concentrations over time (N=17)
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Discussion
From this prospective study, we can conclude that the salivary flow and DQ 
dropped effectively after injection with BoNT. We also observed that this positive 
outcome was accompanied by an increase in salivary mucin concentration. 
Therefore, this study supports the hypothesis that problems with masticatory and 
swallowing functions may be due to changing viscoelastic properties of saliva 
after Botulinum Toxin A treatment.
In the present study, sampling errors due to incorrect saliva collection methods 
were ruled out. The swab method proved to be a highly reproducible and reliable 
method in children with disabilities 1819. In addition, any differences in saliva 
composition between individuals due to circadian rhythms in flow and composition 
can be excluded 20. It is possible, however, that some variability in salivary mucin 
concentration was caused by the swab method used, because the proteins in the 
saliva samples collected by this method are more variable compared to those 
from other saliva collection methods 21. On the other hand, the distribution of 
salivary substitutes differs individually in general. Therefore, the wide distribution 
of the salivary mucin concentrations in our study population may be accepted as 
normal 22. Furthermore, the rheological measurements in this study were accurate 
by using large flexible macromolecules, such as mucins, and their concentrations 
were calculated correctly 17. The accuracy of the salivary flow rates based on the 
gauze weight method, however, may be diminished due to salivary density 
changes after administration of BoNT. The effect of these changes on the gauze 
weight method have not been investigated. However, the density of salivary 
protein is in the range of 1 promille. So it is reasonable to assume that in case of 
density changes the shift in protein content might be minor. Therefore, we think 
that the influence of the density changes did not hamper our findings. The main 
remaining limitations of this exploratory study are the small number and the 
heterogeneity of the participating children, as well as the short time of follow-up. 
Since approximately 20 % of the measurements were randomly missing, a 
sensitivity analysis was done using scenario studies to evaluate to what extent 
these missing data might have influenced the inferences drawn from the data. In 
the LOCF scenario, the last observation before the one missing was used to 
replace a missing value; in the worst case analysis, the baseline value was used 
to replace a missing value. Replacement by baseline values potentially causes a
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serious “bias” towards the null, which implies that a type II error occurred. LOCF 
is a more realistic approach in which one assumes that no changes occur from 
one point in time to the next point in time. When comparing the result of these two 
analyses, statistically and according to content, we got an impression of the 
changes to be expected in these children over time. Notwithstanding 
methodological and power problems, the results of this study demonstrate a 
probable adverse effect after effective management of drooling with BoNT due to 
altered viscoelastic properties of saliva.
BoNT blocks the cholinergic (parasympathetic) component, which is responsible 
for the fluid discharge, with a concomitant increase in salivary substitutes 
concentrations. Former biochemical studies showed that Botulinum Toxin did not 
affect protein discharge 11,12. However, previous studies focused on the effect of 
BoNT on salivary proteins such as secretory immunoglobulin A (immune system) 
and amylase (digestion), but salivary mucins, responsible for the rheological 
properties of saliva, have not been studied before 1112. In contrast to the secretion 
of the other salivary proteins, the secretion and the function of salivary mucins are 
dependent on water 10. In case of dehydration, mucins might be secreted in plugs 
instead of a smooth film of mucus 23. This phenomenon might by analogous to 
cystic fibrosis (CF) lung disease, in which altered fluid secretions across tracheal 
glands, an atypical mucin network with abnormal rheological properties, and 
altered mucus clearance may be responsible for airway “plugs” which are 
characteristic for the disease 24,25. Thus, after management of drooling with BoNT 
injections, the ineffective salivary mucus film may cause more friction leading to 
incomplete wetting of the oral cavity and moistening of food which hampers 
mastication, swallowing, and speech.
It is hard to predict which children with CP and drooling treated with BoNT will have 
side effects due to thickened saliva. In normal subjects, the concentrations of salivary 
substances vary between individuals. This variability in salivary molecule 
concentrations precluded the use of saliva for diagnostic purposes to predict oral 
dysfunction 22. This may also be the reason for the failure to show a correlation 
between the increased mucin concentrations and swallowing problems in the 
present study. On the other hand, it seems reasonable to assume that drooling CP 
children with the most severely disturbed coordination of tongue mobility and lacking 
voluntary control of lips, jaw, and tongue have insufficient strength to process the 
thickened saliva and have problems to clear the oral cavity.
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The largest salivary flow reduction was achieved within eight weeks after 
botulinum application. This corresponds well with the time interval known from 
other studies 112. The largest flow reduction coincides with the expectations that 
the clinical phenomenon of salivary thickening will appear in this period, just as in 
our population.
In conclusion, drooling can be treated effectively with BoNT injections. However, 
in some instances this may lead to thickened saliva causing mastication and 
swallowing problems. This study is the first to support the notion that the viscoe­
lasticity of saliva changes after BoNT application. We observed that the swallowing 
function might worsen after BoNT injection in a group of children, of which most 
had CP but two intellectual disability. This work is relevant because it may be 
expected that the changed viscoelasticity influences the sensitivity of the mouth, 
the sensory perception, and the oral processing of food, and may have 
implications for oral health. In the management of drooling in children with CP, the 
risk of thickening of saliva after BoNT treatment should be taken into account. It 
is advisable to analyse the oral motor functions before treatment decisions. 
However, the supposition of changed rheological properties of saliva after 
submandibular Botulinum Toxin A application deserves further critical reflection 
and additional systematic studies.
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CHAPTER 8
Abstract
Many individuals with neurological problems or anatomical abnormalities of the 
jaw, lips or oral cavity may drool, which can impact on health and quality of life. 
A thorough evaluation of the patient’s history, examination of the oral region by a 
speech pathologist and, in individuals over 3 years, a dental examination is 
warranted. Questionnaires with established validity such as the Drooling Impact 
Scale are useful assessment tools. A hierarchical approach to treatment is taken 
from least invasive therapies, such as speech pathology, to more invasive, such 
as injection of Botulinum neurotoxin type-A (BoNT-A) into the salivary glands 
(parotid and submandibular). The wishes of the individual and their carer are 
crucial considerations in determining the suitability of the intervention for the 
patient. In the presence of dysphagia and cerebral palsy (CP), careful assessment 
is required prior to the injection of BoNT-A. Favourable responses to intervention 
include a reduction in the secretion of saliva and in drooling, as well as 
psychosocial improvements. BoNT-A is usually well tolerated, although potential 
side effects should be discussed with the patient and carer.
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Introduction
Drooling is one of the most significant problems impeding socialization, 
interpersonal relationships and integration into society for individuals with 
disabilities.1-4 The constant presence of saliva may impair articulation and effective 
communication. The appearance and odour in combination with salivary spray 
when the individual talks or coughs results in social alienation. Drooling may 
cause health problems, the skin around the chin and perioral area may be 
chronically irritated causing troublesome rashes, and inadequate swallowing of 
saliva leads to aspiration, which may cause pneumonia. Individuals who drool 
may be perceived adversely with an underestimation of intellectual abilities and 
exclusion from normal peer activities.4-8
Objective
This is an international consensus statement defining the assessment, intervention 
and aftercare of patients with drooling treated with Botulinum neurotoxin type-A 
(BoNT-A) based on the best available evidence. The purposes of this evidence- 
based consensus document are to assist clinicians with the assessment, 
intervention and management of children and adults with drooling and to identify 
areas for future research based on gaps in the literature. These individuals have 
a range of underlying conditions. Literature was searched and appraised using a 
conventional evidence hierarchy. The highest levels of evidence available were 
used to develop recommendations, with randomized controlled trials (RCTs) and 
systematic reviews preferentially sought. Only when RCT or systematic review 
evidence was not available was lower level evidence and practice-based evidence 
included to answer clinical questions raised at the International BoNT Consensus 
Workshop. Expert opinion, where included, has been clearly labeled and should 
be interpreted with judicious caution. Recommendations for research were made 
based on the gaps identified in the literature. All recommendations were graded 
based on the American Academy of Neurology evidence classification.9 The team 
that developed this document included a paediatrician, neurologist, speech 
pathologist, rehabilitation physician, and maxillofacial surgeon.
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Definition
No generally accepted definition exists for the term ‘drooling’. Drooling is also 
termed ‘dribbling’ and ‘saliva loss’. Blasco’s definition (1992) is often quoted: 
drooling is the unintentional loss of saliva and contents from the mouth’.4 
Salivation means the secretion or production of saliva. Normal salivation is poorly 
quantified but it is generally accepted that adults produce 1000-1500 ml of 
saliva per day.10-12 Children prior to puberty produce significantly less (750-900 ml 
per day). Hypersalivation means the excessive production of saliva and is 
synonymous with sialorrhoea. No clear clinical criteria exist to describe hyper­
salivation or pathologic saliva production. In itself, an overproduction of saliva is 
of little clinical relevance if saliva management in the oral cavity is adequate. The 
majority of individuals with cerebral palsy (CP) produce normal amounts of saliva. 
There is some evidence that patients with Parkinson’s disease (PD) produce less 
saliva than normal.813
The International Classification of Functioning, Disability and Health (ICF) refers 
to drooling as an impairment that involves disturbed intake of liquid (or solid) 
substances from the mouth to the digestive system. Although it correctly refers to 
the shortcomings in oral function or structure, this definition is not a useful 
description for clinical use.
With respect to aetiology and clinical impact, it is advisable to distinguish anterior 
drooling from posterior drooling. Saliva spilled from the mouth is referred to as 
anterior drooling, which is clearly visible. Posterior drooling is where saliva is 
spilled through the faucial isthmus creating a risk of aspiration.14,15 Posterior 
drooling occurs in patients with severe oropharyngeal dysphagia.16 Anterior and 
posterior drooling may occur at times in the same individual.
Aetiology
Drooling is normal in the growing child up to the age of 18 months. Beyond the 
age of 4 years, it is abnormal5 and frequently persists in children with poor 
neuromuscular coordination, intellectual or learning disabilities, as well as in 
patients who have lost the structural integrity of their jaws, lips or oral cavity.6 
In addition, adults presenting with dysphagia with neurological disease such as
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Recommendation 1
*Expert opinion.
In summary, the following is recommended:*
• To define the term ‘drooling’ as: the unintentional loss of saliva from the mouth
• That the terms anterior and posterior drooling should be distinguished
PD and motor neuron disease (MND) may have associated drooling.7,8,17 
Drooling can vary from minute to minute depending on factors such as hunger, 
thirst, fatigue, anxiety, excitement and the circadian rhythm of saliva production 
over time.
It is widely accepted that drooling in CP is not caused by hypersalivation, but 
rather by oral motor dysfunction.3 An exception to this may be for those with 
dyskinetic disorders where the abnormal movements may constantly stimulate 
the parotid glands to produce more saliva.18
The aetiology of drooling is multifactorial. In most individuals who drool, intraoral 
saliva management is disturbed to some extent. These individuals may 
demonstrate a variety of symptoms because of sensorimotor impairments, or 
there may be anatomical abnormalities.18 Inadequate lip closure, habitual 
open-mouth posture, ineffective or limited tongue movements, poor coordination 
between the oral and pharyngeal stages of swallowing, malocclusion, flexed 
posture, gingivitis, and dental caries may contribute to the origin of drooling.19,20 
In PD, there is evidence (Class III) that dysphagia, as a result of an impaired oral 
and pharyngeal stage of swallowing, positively correlates with drooling severity.7,21
Epidemiology
The prevalence of drooling has been infrequently studied, and the results cannot 
be compared as a result of variation in research design, patient selection, and 
data presentation. Quantification of salivary flow rate or drooling is challenging.10 
In previous CP studies, about 10% of a Swedish population of children with CP 
showed ‘embarrassing drooling’.22 In another study, moderate to severe drooling
115
cHApTER 8
occurred in 10-37.4% of individuals.23 Furthermore, the prevalence of drooling 
was investigated in a population of children with CP across dental age and of the 
total population, 58% had some degree of drooling (33% severe drooling, 9% 
moderate drooling and 16% mild drooling). The authors concluded that the 
degree of drooling decreased as the dental age increased.24 A Spanish research 
group evaluated 50 individuals with CP, both children and adults, and 58% had 
drooling (mild in 44.4% and moderate to severe in 27.7%).25 
Although no definite conclusion can be drawn from the literature, it seems 
reasonable to accept that one out of three individuals with CP drools to some 
extent. A recent study reported that drooling occurs in 70-80% of patients 
with PD.10
What is the best way to assess?
As drooling is a multifactorial problem, a range of assessments are required, 
undertaken, ideally, by a multidisciplinary team.
As drooling varies throughout the day, accurate measures have been difficult to 
achieve. Assessment begins with an investigation of the patient’s goal for 
intervention, which may be for the purposes of social wellbeing. In the case of 
posterior drooling, a medical goal (no or less aspiration) can be defined.
The initial patient interview includes a thorough evaluation of the medical and 
social-emotional history of the patient and consideration of aetiology. Our 
approach is similar to that described previously (see Table 1).26 Exclusion of 
upper airways obstruction is important. Some medications may be associated 
with excessive salivary secretion. Assessment by a speech pathologist is essential 
to consider trialling the most appropriate and least invasive oromotor interventions. 
A dental examination is recommended for all individuals over the age of 3 years 
as carious teeth or poor dental hygiene can contribute to excessive salivary 
secretion. If BoNT-A is the preferred option, it is important to discuss realistic 
goals. This dialogue is informed by the clinician’s understanding of the medical 
history and assessment of the patient’s symptoms and their relative contribution 
to drooling.
A summary of recommended assessments is listed in Table 2. Measures that 
have been used to quantify salivary flow include the collection of saliva in bags or
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Table 1 Assessment by members of a ‘drooling team’
The team may include several of the following: dentist, ENT specialist, neurologist, nurse 
practitioner, occupational therapist, paediatrician, physiotherapist, plastic surgeon, 
psychologist, rehabilitation specialist, speech pathologist.
Assessment includes:
• Medical, social-emotional history of the patient, motivation, individual’s ability to 
participate
• Medication (anticonvulsants, benzodiazepines, neuroleptic drugs)
• Respiratory status (cough, wheezing, recurrent pneumonia)
• Presence of allergy leading to a problematic increase in secretions
• Presence of gastro-oesophageal reflux, which, if severe, can be associated with 
hyperstimulation of the salivary glands
• Nutrition and hydration
• Neurological examination (alertness, cranial nerves, general motor skills/posture 
and tone)
• Orofacial examination (nasal breathing, upper airways obstruction)
• Oral hygiene, occlusion and dental health, dental examination 
Assessment by a speech pathologist:
• Head control
• Mouth closure, occlusion, lip seal
• Oral sensorimotor examination (tongue lateralization, sensation, tone)
• Oropharyngeal stage of swallowing during eating and drinking (swallow on demand, 
frequency/efficiency)
• Speech (dysarthria/dyspraxia)
• Communication skills
• Management of secretions
chin cups (Lashley cup)27,28 or by weighing bibs.29 There are difficulties in ensuring 
accuracy with all these somewhat intrusive methods. These methods are more 
suited to research studies, along with the use of dental cotton rolls, suctioning 
saliva and, more recently, micropipette retrograde cannulation of major salivary 
gland ducts, which allows an accurate measure of flow and consistency. All of 
these methods measure the quantity of saliva secretion rather than the poor oral
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Table 2 Recommended assessments
Assessment Purpose Who does it ICFa domain 
measured
Properties Clinical utility
international Classification of Functioning, Disability and Health (ICF): valuable information can be found in the chapters about Body structures & 
Body Functions (S5, B5), Activity and participation (D7) and Environmental factors (E3). For children, the ICF-CY version should be reviewed.
Speech
pathologist
exam
Examination of 
positioning, oral 
functions, speech 
and swallowing
Speech pathologist Body structure: nose, dental, 
mouth, pharynx (s310-S330) 
Structures of head and 
neck region) (s710) Body 
function: sucking, biting, 
chewing, manipulation of 
food, salivation, swallowing 
(b5100—5105) Body function: 
speech, voice, articulation 
(b310-399)
Expert opinion to 
support decision 
making on treatment/ 
intervention
Drooling
Quotient
Quantitative scores 
of drooling
Nurse/speech pathologist/ 
carer/teacher
Body function: salivation 
(b5104)
Validated 
instrument to 
express the 
severity of drooling
Score on a numerical 
scale
Drooling 
Severity and
Outcome on an 
ordinal scale
Nurse (practitioner)/speech 
pathologist
Structured 
inventory, not
Score which is indicative 
of the severity and
Frequency
Scale
validated, easy 
to use in clinical 
practice
frequency of drooling
C
H
A
P
T
E
R
 
8
Drooling Questionnaire to Individual, carer or person
Impact (Drl) assess the effect who knows the individual
Scale of saliva control well
interventions on
drooling in children
with developmental
disabilities
Salivary flow Measure saliva Speech pathologist or any
secretion in ml/min other well-instructed team 
or g/min member
Participation Valid, reliable Free, no training
(test-retest), required, <5 min
responsive to to score, carer self­
change administered, over 
phone or in person
Body structure: salivary Variable outcome Research purposes
gland (s510) with intra-and inter­
individual variation, 
but reliable 
for research 
purposes with 
larger numbers of 
patients
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CHAPTER 8
motor control that is primarily responsible for drooling, although they may be 
useful as most treatments, such as BoNT and medication are designed to reduce 
salivary flow. More invasive techniques such as the use of radioactive isotopes 
have also been used but are contraindicated for safety reasons.30 
A less invasive measure is the Drooling Severity and Frequency Scale (DSFS), 
which measures the severity, and frequency of drooling.31,32 It gives an impression 
about the dimensions of drooling and can be used for studying outcomes. The 
ordinal scale makes it useful for statistical purposes. When the DSFS has been 
used for parent report after surgery31, a greater reduction in severity than 
frequency has been reported, demonstrating lack of concordance with the 
patient’s or caregiver’s opinion.
Over the last few years, subjective questionnaires have been developed to record 
the views of the carer or patient.33 34 If constructed carefully in relation to content 
and construct validity, they can be sensitive enough to reflect the concerns of 
parents or carers and to measure clinical change. One of these is the Drooling 
Impact Scale35, which consists of ten items, rated on a 1- to 10-point scale. The 
individual patient, their carer(s), or someone who knows the patient well completes 
the questionnaire. The assessment reflects the changes in drooling as perceived 
by the person completing the questionnaire.
The measurement of drooling by observing the number of drips of newly formed 
saliva at the lips over a period of time and converting the result into a ‘drooling 
quotient’ (DQ) has also be trialled. This method is difficult to execute and has the 
prerequisite of a clear definition of drooling that is to be scored with precise time 
intervals. The DQ is a semi-quantitative observation method, which gives a 
number on a numerical scale reflecting the severity of drooling.36 37 It may be used 
for research and clinical purposes.
For PD, there are two specific scales that may be helpful. Subheadings of the 
Unified Parkinson’s Disease Rating Scale (UPDRS)38 may be used, and the 
Sialorrhea Clinical Scale for Parkinson’s Disease (SCS-PD) is a validated scale 
that specifically measures drooling related discomfort.39
Radiographic swallowing studies are available to study the separate phases of 
swallowing and to detect aspiration as an indication of ‘posterior drooling’. These 
studies do not prove that posterior drooling is occurring but can suggest its 
presence and can be used in conjunction with a medical history of recurrent 
aspiration or pneumonia.
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Which patients should be treated?
Recommendation 2
*Expert opinion.
A. A thorough assessment is recommended, and therapy based on:*
• A thorough evaluation of the medical and social-emotional history of the patient
• Examination of the oral region by the speech pathologist
• A dental examination in individuals greater than 3 years of age
• Questionnaires with good content and construct validity such as the Drooling Impact 
Scale
B. Assessment for research purposes may include additional measures, for example, 
the Drooling Quotient or the measurement of salivary flow.
Much information is available as to which patients might benefit from BoNT-A 
injected into the salivary glands, but few studies provide evidence of its 
effectiveness. Given it is an invasive procedure, there should be a significant 
problem with drooling for BoNT-A to be indicated, although there is an argument 
that drooling even small quantities can be socially disadvantageous and mitigate 
against successful integration into home, school and the community. The most 
important factor in determining whether a child or adult should be treated is the 
wishes of the individual or their carer to control the problem, with the hope of 
enhancing quality of life and participation.
Groups of patients that drool include those with CP; intellectual disability; 
acquired brain injury; neurodegenerative disease, for example PD and MND; 
post-cerebrovascular accident; oromandibular patients, for example those with 
head or neck carcinoma; sialadenitis; salivary fistula; and other more unusual 
neurological conditions, for example Moebius syndrome.40 
The spectrum of conditions is obviously very wide, but there are potentially large 
numbers of individuals who could benefit from this treatment if it were more widely 
available.
121
cHApTER 8
Those that should be excluded
1. Individuals or carers who do not wish to control the drooling problem.
2. It is important that the clinician is aware as to whether BoNT-A has been used 
in other sites in the previous 4-6 months and works closely with other 
clinicians who may be injecting into other sites. Repeated injections within an 
interval of <3 months enhance the risk of antibody formation.
3. Patients unfit for anaesthesia or sedation, where these procedures are 
necessary for treatment. In adults, sedation is very rarely necessary for BoNT 
injection. Moreover, older children can sometimes be treated using local 
anaesthesia.
4. Patients that have developed antibodies to BoNT-A. These individuals may, 
however, be treated with an alternative BoNT formulation.
In our experience, the clinical development of antibodies is rare, as determined 
by the development of resistance to treatment, and the presence of antibodies 
does not consistently correlate with absence of effect.41 If antibodies to BoNT-A 
develop, the use of BoNT-B can be considered.42 In the presence of pre-existing 
swallowing problems, careful assessment and monitoring must be provided. 
Patients with pre-existing dysphagia, particularly those with CP and Gross Motor 
Function Classification System level V (GMFCS V), may be at higher risk for 
adverse events and must be assessed very carefully prior to injection.43 
Potential alternative treatments:
1. Behavioural approaches
2. Medication
3. Oral appliances
4. Surgery
Timing of intervention
Little information is available to provide a recommendation about optimal timing, 
but there should probably be a 4- to 6-month time interval between each 
treatment. The manufacturer of BOTOX® advises a minimal interval of 3 months.44 
Gaining adequate saliva control prior to winter is important because drooling is 
an added burden in the presence of respiratory infections. It is important to define 
priorities with family members and clinicians who may be wishing to inject BoNT-A 
into other sites of the body.
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Recommendation 3
*Expert opinion.
It is recommended that BoNT-A should not be administered:*
• If BoNT-A has been given for any reason in the previous 3 months
• If the patient has antibodies against BoNT-A
• I f the patient is unfit for sedation or anaesthesia (this mainly relates to children as 
adults may have treatment without anaesthesia)
In the presence of dysphagia and CP with GMFCS level V, careful assessment should 
take place prior to injection.
Acquired resistance to BoNT therapy is a well-recognized phenomenon, marked by lack 
of beneficial effect. It is recommended that BoNT-B be tried after treatment failure with 
BoNT-A or vice versa.
What is the optimal Botulinum Toxin intervention regimen?
Rationale fo r treatment
Intraglandular delivery of BoNT-A inhibits the release of acetylcholine from 
cholinergic nerve endings and consequently reduces the secretion of saliva and 
diminishes drooling in the majority of patients.
Intervention options
Several prospective, controlled clinical trials have investigated BoNT-A and 
BoNT-B injections in the treatment of drooling.1735 45-55 A significant reduction in 
saliva was found using objective methods47,50,56 (Class I) as well as subjective 
evaluations in these studies.50 51 56 Supportive evidence for the efficacy of BoNT-A 
can be derived from two other articles.57,58 In addition, BoNT-B has been shown to 
be equally effective and with similar side effects in a study of 30 children with CP 
or neurodegenerative disorders.59 Injection sites include the submandibular 
gland, parotid glands or both and should be undertaken using ultrasound 
guidance to ensure delivery into the submandibular glands.51,56,60 Recommenda­
tions for dosing and injection sites are outlined in Table 3. The use of ultrasound 
guidance for the parotids is also advisable, although experienced clinicians may 
rely on landmarks.11,4748,50,57
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Table 3 Injection site, dose and injection proceduresa
a Different preparations are available e.g. BOTOX®, Dysport®, Myobloc®. All data reported 
here are from the published literature. BOTOX® and Dysport® are not exchangeable. 
Research suggests (level 3) that 1 Unit of BOTOX® equates to approximately 3- 4 
Units of Dysport® but since the units are not interchangeable, to improve safety it is 
recommended that professionals follow manufacturer’s dosing guidelines and do not 
use approximate conversions.
Injection Site BOTOX® Dysport® Myobloc® Injection Procedures
u u u
Submandibular gland 10-50 15-75 250-1000 Percutaneous injections, 
ventral approach, one 
injection/side, use of US, 
general anaesthesia (mainly 
in children)
Parotid gland 10-50 15-75 400-1000 Idem
Recommendation 4
*Expert opinion.
The following is recommended:
• I njection of BoNT-A into the salivary glands (parotid and submandibular) ideally under 
ultrasound guidance*
Tables 4 a,b list the Class I, II and III studies that have been undertaken in children 
and adults, respectively, to evaluate the efficacy of BoNT-A and BoNT-B.
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Table 4 Evidence for use of Botulinum Toxin (a: paediatric drooling, b: adult drooling)
Reference Design Participants Intervention Outcomes
a: paediatric drooling
Alrefai AH e t al. 
Clin N eurol 
N eurosurg ; 200949
RCT A/=24 (15 males,
9 females)
Age: 21 months to 
7 years
CP & significant 
drooling
BoNT-A
(Dysport®):
100 U or normal 
saline into the 
parotid glands 
bilaterally
Scores of median frequency 
(P = 0.034) and severity 
(P = 0.026) were reduced in 
the treatment group
Banerjee KJ e t al. 
Dev M ed  C hild  
Neuro l; 20 0661
Clinical 
study without 
randomization. 
Drooling assessed 
at baseline, and 4 
and 12 weeks
N=2Q (10 males, 
10 females)
Age: 6-16 years 
CP & significant 
daily drooling 
(1 discont.)
BoNT-A: 2 U/kg; 
maximum 70 U; 
1.4 U/kg parotid 
gland; 0.6 U/kg: 
submandibular 
gland
Drooling frequency and 
severity scores (Qualitative) 
significantly reduced at 
4 weeks (P < 0.001) and 
12 weeks (P = 0.006).
QOL scores (Qualitative;
Adverse Events
active treatment 
group reported a 
transient increase 
in drooling after the 
injection
No side effect from 
injections
rated by parents and teachers 
separately) significantly 
improved (P < 0.001 and 
P = 0.023 respectively). 
Number of bibs/ 
scarves changed per 
day (Quantitative) was 
significantly reduced at 
4 weeks (P < 0.001).
Evidence
(AAN)
Class I
Class III 
(pts are 
own controls)
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126 Table 4 Continued
Jongerius PH 
et a I. Pediatrics; 
20 0445
Controlled, open- 
label clinical trial
N =45 (28 males, 
17 females)
Age: 3-17 years; 
mean 9.5)
CP & severe 
drooling 
Not previously 
treated with BoNT 
(6 discont.)
Single-dose 
BoNT-A (BOTOX* 
injections 
(submandibular 
glands) versus 
scopolamine 
30 U BoNT-A if 
<15 kg, 40 U if 
15-25 kg, 50 U if 
>25 kg
Drooling reduced with 
scopolamine and with BoNT 
injections.
Greatest reductions in DQ
were achieved
2 - 8  weeks after BoNT.
No sig diff (DQ) between 
scopolamine & BoNT 
injection during 24 weeks. 
VAS (parents): 
sig diff from baseline in all 
follow-up assessments. 
‘Success’ (2-point decrease 
on TDS): 61.5% BoNT pts. 
Response rate (DQ) of 53% 
of pts to scopolamine and 
48.7% to BoNT until 24 weeks
Scopolamine AEs 
reported in 82.2%:
5 (11.1%) mild,
14 (31.1%) 
moderate, and 
18 (40%) severe 
AEs.
Xerostomia (66.7%),
restlessness
(35.6%),
somnolence
(35.6%),
blurred vision
because of pupillary
dilation,
confusion (20%). 
BoNT injections:
2 (5.1%) transient 
flu-like syndrome 
(<2 days),
3 mild difficulty with 
swallowing.
Jongerius PH Controlled clinical N  =45 Single-dose
et al. Neurology; trial Age: school aged BoNT-A injections
200446 CP with sialorrhoea (submandibular
glands) vs 
scopolamine;
30 U BoNT-A if 
<15 kg,
40 U if 15-25 kg, 
50 U if >25 kg.
Mean decrease in 
submandibular flow 
25% during scopolamine, 
42% following BoNT (from 
baseline).
Response rates for BoNT 
were
sig lower, varied from 69% at 
2 weeks to 49% at 24 weeks 
after injection
4 pts discont. 
scopolamine due 
to AEs
Mild incidental AEs 
reported from BoNT
Class II
Class II
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Ong LC et al. J  
Ped ia tr Neurol; 
20 0952
Descriptive, open- 
label, non-blinded 
prospective trial
N =21
Age: mean age 
8.4 ± 2.5 years 
CP
60-80 U BoNT-A 
(Allergan®);
15 U into each 
parotid gland;
<15 kg 15 U, 15- 
25 kg 20 U, >25 kg 
25 U into both 
submandibular 
glands
Improvement on DSFS, DQ, 
number of
bibs changes per day, VAS, 
decrease in QoL scores 
within 16 weeks after injection
Pain and swelling, 
thick saliva, 
difficulty chewing in 
first 2 weeks after 
BoNT injection
Class III
Reid SM e t al. Dev 
M ed C h ild  N eurol; 
20 0835
Prospective RCT; 
multicentre
N =48 (27 males, 
21 females)
Age: mean 11 
years to 4 months, 
range: 6-18 years 
Drooling & CP & 
other neurological 
disorders
BoNT-A injections 
(25 U) into 
submandibular & 
parotid glands (tx 
n = 24), control: 
no tx)
Max response was at 1 month 
(assessed by carers using 
DIS); Highly sig diff in mean 
scores between groups 
at 1 month.
This diff remained significant 
at 6 months, 4 children failed 
to respond to the injections, 4 
had mediocre results, and 16 
had good results
One child had 
difficulties with 
swallowing and 
deterioration 
of speech for 
5 days following 
injection, another 
child developed a 
chest infection on 
day 5, and a third 
child had his first 
seizure 2 days post­
injection
Class I
Savarese R e t al. 
Am  J Phys M ed  
Rehabil; 200462
Open-label, 
non-blinded, 
prospective study
N =21
CP & problematic 
drooling
15 U BoNT-A 
into each parotid 
gland.
Improvement on VAS, number 
of bibs used/day.
Weight of dental rolls: 53% 
marked improvement, 11% no 
response
None Class III
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Table 4 Continued
Suskind DLef a/. Prospective N =22 1st group (n =  12) All subjects successfully No local or systemic Class II
Laryngoscope-, open-label, dose- Age: 8-21 years injected into only underwent BoNT-A injections. complications
20 0263 escalation study CP & sialorrhea the submandibular 
gland (10, 20 or 
30 U BoNT-A)
2nd group (n = 10) 
injected into the 
submandibular 
(30 U) and parotid 
glands (20, 30, or 
40 U)
Objective ‘drool 
quantification’ with dental 
rolls extremely difficult.
Most indicative of results 
was the “drool rating” 
questionnaire and the DQ
No adverse effects 
on swallowing
b: adult drooling
Jackson CE e t al. 
M uscle  & Nerve; 
2009 ' 7
RCT N =20 ALS BoNT B
(Myobloc®) into 
parotid and 
submandibular 
glands; 500 U 
into parotid gland 
and 750 U into 
submandibular 
gland
Improvement on VAS and 
QoL scores; 50% of patients 
report improvement at 
12 weeks post-BoNT
None Class I
Kalf JG ef al. Clinical study, A/ =17 PD, BoNT-A Successful outcome: post­ Some side- Class II
Parkinsonism independent UPDRS 2 points (Dysport®), total treatment score of 1 (slight) effects: transient
Relat investigator or higher, DSFS 3 dose 150 MU or 0 (normal) on the UPDRS swallowing
D isord;200755 assigned to one of 
the groups using 
a list of random 
numbers
points or higher 1st group 
injected into 
submandibular 
glands bilaterally 
2nd group 
injected bilaterally 
in the parotid 
glands
drooling scale difficulties, 
xerostomia at night
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Lagalla G e t al. 
M ov D isord; 
200650
RCT N =32 PD 50 U BoNT-A per 
parotid gland
Lipp A e t al. 
N euro logy; 200347
RCT (Single-centre, 
prospective, 
double-blinded, 
placebo-controlled, 
dose-finding study)
N =32 BoNT-A
(Dysport®) 18.75, 
37.5, and 75 MU 
per parotid gland
Mancini F e t al. 
M ov D isord;
20 0351
RCT N =20 PD BoNT-A 
(Dysport®) 
146.25 U per 
parotid gland; 
78.75 U per 
submandibular 
gland
Ondo WG e t al. 
N euro logy;
20 0448
Double-blinded
placebo-controlled
trial
N =16 (13 maies, 
3 females)
Age about 
70 years; 
duration of PD 
about 12 years
BoNT-B injections 
1000 units at two 
sites into each 
parotid gland 
and 250 units at 
one site into each 
submandibular 
gland (total of 
2500 units)
00
Improvement on VAS, 
UPDRS-drooling, dental roll 
weight compared to placebo
None Class I
Primary end-point was 
achieved with 75 MU BoNT-A
No treatment- 
related AEs
Class I
Improvement on DSFS 
compared to placebo
None Class I
Improvement on VAS. Global 
impressions of change 
Drooling Rating Scale.
No change in UPDRS, head 
posture of dysphagia scale
Side effects mild 
and included dry 
mouth (3 patients), 
worsened gait (2 
patients), diarrhoea 
(1 patient) and 
neck pain (1 
patient)
Class I
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3
0 Table 4 Continued
Porta M e t al. J 
N euro l N eurosurg  
Psychiatry; 200164
Open-label N =10 PD, ALS, 
CP
Mean 27.7 U 
BoNT-A per 
parotid gland, 
mean 11.9 U per 
submandibular 
gland
Improvement on VAS None Class III
Racette BA e t al. 
M ov D isord;
20 0353
Open-label pilot 
study
N =9
Parkinsonism
1000 U BoNT-B 
(Myobloc®) into 
each parotid 
gland
Improvement of 2.4 points 
on VAS (from 0 to 4, where 0 
indicated no drooling and 4 
indicated worst drooling) 
Mean flow reduction of 42%.
Dry mouth, 
resolved within one 
month
Class III
Abbreviations; QOL, Quality of life; ENT, ear, nose and throat; Discont, discontinued; Tx, treatment; DQ, drooling quotient; VAS, Visual analogue scale; DSFS, 
Drooling Severity and Frequency Score; UPDRS, Unified Parkinson’s Disease Rating Scale; BoNT, Botulinum toxin; Sig diff, significant difference; Pts, patients; AEs, 
adverse events; RCT, randomized controlled trial; DIS, Drooling Impact Scale; MND, motor neuron disease; CP, cerebral palsy; PD, Parkinson’s disease
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What are the optimal adjunctive interventions?
A hierarchical approach to treatment for poor saliva control is taken from the least 
to the most invasive treatments.65 These treatments, which may be undertaken 
concurrently, commence with speech pathology (oral sensorimotor therapies, 
developing eating skills), occupational therapy and physiotherapy (posture and 
seating), psychology (behavioural programs), and dentistry (maintenance of oral 
health and appliance therapy). In certain parts of the world, there are intensive 
behavioural therapies available involving a psychologist, whereas in other places, 
behavioural advice is given by a range of health professionals (see Table 5). 
Medication is sometimes trialled along with behavioural intervention and/or 
sensorimotor programs and may be provided when the drooling is causing the 
individual distress in social settings e.g. in the first year of school. Behavioural 
interventions directed at self-management (improvement in swallowing and 
wiping of the mouth), may be more effective when paired with medication to 
provide an opportunity for a child to experience positive feedback from having a 
dry chin. There is clear evidence to support short-term positive results from 
behavioural interventions; however, many studies are small in number, use a wide 
range of treatments and lack specificity in measures.66 Although further studies 
are needed to provide evidence of long-term improvement, a start has been 
made to determine the efficacy of behavioural programs.67 As BoNT-A injections 
provide short-term relief from drooling, repeated injections are unlikely to be a 
permanent solution, providing a challenge to develop other more long-term 
options.
What are the expected outcomes of Botulinum Toxin therapy?
A favourable response to intervention is improvement in pathophysiological 
aspects such as a reduction in the secretion of saliva and reduction in drooling. 
Psychological and sociological improvements may also be expected from 
intervention for drooling.
How should patients be monitored?
Before starting intervention, patients should be informed about the potential risks 
and adverse events associated with BoNT-A. It is usually well tolerated; however, 
side effects can occur. Efforts should be made to reduce or prevent these.
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Adverse effects
• To avoid serious side effects, BoNT-A should always be injected under optimal 
conditions with the patient lying quietly (sedation or anaesthesia if needed) and 
under ultrasound guidance.
• Repeated injections may be needed, and therefore, pain and anxiety should be 
minimized.
• No fatal side effects have been reported in the literature. There are a multitude of 
potential side effects, and the patients should be carefully monitored.
• Possible adverse effects during or following the injection include the following:
Adverse effects relating to trauma at the site of the injection
• Pain (not severe) at the injection site either during the procedure, or because of 
gland swelling (hours) or haematoma formation (days) following the procedure
• Haematoma in the peri-glandular region caused by bleeding from the skin or 
subcutaneous tissue
• Intraoral blood caused by intraglandular/transductal bleeding
• Swelling of the gland caused by bleeding or injection of too large a volume of 
solution
• Swallowing problems caused by swelling of the gland, which usually resolves 
within 2 hours
• Infection
• Theoretical possibility of trauma to the facial nerve when injecting the parotid
Adverse effects relating to BoNT-A and BoNT-B
• Increased dryness of the mouth leading to problems such as manipulation of 
solid food
• Thickening of saliva because the water component is influenced by cholinergic 
blockade leading to an increase in the concentration of mucins and proteins
• Chewing and swallowing problems because of diffusion of BoNT-A into the 
surrounding muscular tissue. Careful attention should be paid to eating and drinking 
abilities during the week following injection. When injecting the parotid, diffusion of 
BoNT-A into the masseter muscle is possible, causing weakness in chewing
• Loss of BoNT-A because of intravascular injection (without systemic consequences 
because of the low dosages used; however, iatrogenic botulism has been 
reported in a single case)
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Recommendation 5
*Expert opinion.
The following is recommended to avoid or limit adverse events with the use of BoNT 
therapy:*
• The use of ultrasound guidance during injections
• Observation of the patients for at least 2 hours following injection
• Regular contact with the patients or caregivers in the week following injection to 
evaluate swallowing problems
• Being aware of the possibility that thickening of saliva over time may occur which 
leads to swallowing and respiratory problems
• Moist or pureed food in the first week following injection
Future directions
Much work still needs to be carried out to improve the management of poor saliva 
control in both children and adults with disabilities. Improved diagnostic and 
therapeutic methodology utilizing real-time imaging modalities would assist in 
better defining the clinical problem and the outcomes of treatment. A better 
evidence base for oral sensorimotor techniques would be useful, along with 
improved methods for neuromuscular control of the upper digestive tract. 
Specific pharmacological control of salivary gland function would avoid some of 
the adverse effects currently encountered when using anticholinergic therapy. In 
addition, endoscopic surgical ablation of major salivary gland tissue or autonomic 
ganglions associated with major salivary glands would avoid the lengthy and 
sometimes difficult surgical procedures that are now undertaken.
With regard to BoNT-A therapy, it is possible that there may be some long-term 
effects gained because clinicians have observed some shrinkage in the size of 
the salivary glands following repeated doses of the toxin. This needs to be studied 
in detail using a research protocol.
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Table 5 Adjunctive interventions55'58-72
Intervention Indications for use
Behaviour Management: 
aims to assist the person to learn to manage 
their own saliva independently e.g. by wiping 
their mouth66'68
Person can comprehend 
instructions, physically 
carry out the task and is 
motivated
Oral Motor Therapy: aims to establish or 
restore oral coordination for eating 
by:
(1) Exercises & stimulation to the face and 
mouth provided to address coordination of 
oral movements & saliva control69
(2) Specific practice of graded functional 
activities involving person, task and 
environment adaptations70
Oral Appliances e.g. ISMAR Good cognition; able
(Innsbruck Sensori Motor Activator to tolerate an oral 
& Regulator): aims to assist with jaw stability appliance, good family
and develop lip and tongue control71 support
Limited chewing and 
swallowing skills; poor lip 
closure; inability to sense 
saliva in and/or outside the 
mouth
Intensity of 
intervention
Classification of 
recommendation: 
standard treatment
Classification of 
recommendation: with 
BoNT-A
Optimal intensity Effective with some Data unknown
is not known groups
Optimal intensity U U
unknown Data inadequate 
Probably effective
Data inadequate
with some tasks
Daily - possibly Effective 
for several years
Not known
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Seating and Positioning: aims to adapt or 
modify a person’s position to enable the 
upright sitting posture for eating, social 
interaction, hand function and mobility.
The intervention involves prescription and 
manufacture of customized seating cushions 
within a wheelchair or stroller72
Inability to sit upright 
for safe swallowing, 
transportation, social 
interaction or hand use
B, probably effective; U, inconclusive
Optimal intensity B U
unknown Probably effective Data inadequate
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SUMMARY AND GENERAL DiSCUSSiON
Summary and General Discussion
The general aim of the research presented in this thesis was optimalisation/ 
refining ultrasound guided submandibular Botulinum Toxin (BoNT-A) treatment 
for drooling in children with cerebral palsy (CP), and to provide basic concepts 
into the mechanisms that underlie the drooling problem. CP is the most common 
cause of physical disability in childhood. Moreover, drooling is a common 
additional impairment hampering the ability of a child to realize his or her intrinsic 
developmental potential. At the time we started our research, submandibular 
BoNT-A injections proved to be effective for drooling control in children with CP, 
however it was unknown why in a number of children drooling control was not 
achieved after submandibular BoNT-A. Therefore, we carried out a prospective 
study in a historic cohort of 151 Dutch children with CP or with exclusively 
intellectual disability.
Chapter 2 describes relevant dysfunctional neuronal networks of swallowing in 
drooling. CP was used as a clinical model to illustrate the comprehensive 
framework crucial for coordinating oral motor and associated (upper and lower) 
gastrointestinal functions. The execution of the sensorimotor aspects of 
swallowing rely on functionally connected pathways between the (extra)pyramidal 
cortical motor planning regions, brainstem controlling centres, cranial nerves and 
lower motor neurons. The site and extent of the brain injury determine the extent 
of the dysfunction. Disturbances in the cortical part of this network result in 
clinical symptoms as oral tone regulation problems, dysfunctional oral control 
(particularly incomplete lip-closure, tongue protrusion, slow and stiff tongue 
movement, diminished oral suction), delayed initiation and segmented swallowing 
during attempted volitional movement. Dysfunctional pharyngeal components of 
swallowing [i.e. automatic components of deglutition, such as throat clearing, 
laryngeal closure tasks] tend to rely on subcortical networks. The ability to plan 
and coordinate swallowing with ventilation activity may also be impaired [for 
example, early inspiration after a thin liquid swallow or variable duration of the 
deglutition apnea] and is consistent with brainstem involvement. It can be 
concluded that the wide range of swallowing, respiration, drooling and GI 
problems can be understood through and are caused by (partial) disruption of 
these swallowing circuitries and the brain-gut axis. It can be concluded that 
dysphagia and drooling are frequently occurring symptoms and long-term
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neurological sequelae. In our opinion and at early stage, particular note should 
be made to the important contribution of dysphagia and excessive drooling to the 
burden of the child with CP and his/her family. In addition, the younger brain is a 
highly dynamic structure with the capacity for profound structural and functional 
adaptation. We think formulation of rational prognostic statements and 
development of appropriate plans of management of dysphagia should be based 
on awareness of the topography of the brain injury. This approach could also 
provide valuable information for the development of more effective intervention 
strategies for dysphagia in future.
Chapter 3 reports on a case-control study. The aim of this study was to investigate 
whether drooling in children with CP in general and in CP subtypes might be 
caused by hypersalivation. Saliva was collected from 61 healthy children and 100 
children with CP who drooled, of whom 53 had spastic, 42 had dyskinetic, and 
five had ataxic CP. Our study supported the finding that no hypersalivation exists 
in children with CP who drool in general. Although we did not find arguments for 
hypersalivation in the total CP group, clinically the drooling in dyskinetic CP 
appears to be a subgroup. The drooling is more intense probably due to 
hyperkinetic oral movements. With mechanical stimulation of the salivary glands 
in these children, the total daily saliva secretion (generally about 600mL) was 
increased by at least 200mL per day. The contribution in added saliva secretion 
of the parotid glands was twice as large as that of the submandibular glands. This 
can be a relevant phenomenon in the management of drooling. Chapter 4 reports 
about the efficacy and durability of submandibular BoNT-A in 131 children. 
Follow-up data after 2 and 8 months were compared to baseline assessments to 
investigate the effect and durability of injection. A clinically notable response was 
found in 48.9% of patients, which was reflected in a significant mean reduction in 
the Drooling Quotient (DQ; 0-100%) from a baseline of 29% to 16% after 2 months 
and 19% after 8 months. The mean Visual Analogue Scale (VAS; 0-100mm) 
showed a similar pattern, falling from 81 to 53 mm after 2 months, but showing a 
noticeable return to baseline after 8 months. Patients who responded to treatment 
after 2 months demonstrated relapse after a median of 22 weeks. Chapter 5 
describes the efficacy of submandibular BoNT-A treatment for drooling and 
mechanisms underlying its responsiveness in 126 children, divided over three 
groups: children with spastic or dyskinetic CP, and children with intellectual 
disability only. The findings suggest that submandibular BoNT-A treatment for
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drooling has similar effects across children with spastic or dyskinetic CP subtype, 
or those with intellectual disability only. Chapter 6 describes the first attempt to 
reveal the contribution of body functions and structures (as defined by the 
International Classification of Functioning, Disability and Health for Children and 
Youth (ICF-CY)) to the outcome of a BONT-A submandibular injections. After 
completing a thorough literature study, we identified that the following factors are 
suggested to contribute to drooling severity: head position, lip seal, voluntary 
control of tongue movements, control of voluntary movement functions, and 
mental age. All five investigated clinical factors seem logical to influence treatment 
outcome. For example head position and lip seal are influenced by gravity. The 
same reasoning also applies to movement functions which are clearly related to 
head position. Previous investigations demonstrate that tongue mobility is 
strongly correlated with drooling and drooling control. Therefore, it seems 
plausible that the ability to control the tongue is an important factor related to 
therapy outcome, following the factor quantity of saliva reduction. Moreover, the 
risk of oromotor impairment is raised by any degree of intellectual impairment and 
therefore the relationship between mental age and therapy outcome might be 
expected. However, the exploration of this five nominated clinical factors did not 
lead to a favorable conclusion in 151 children. The observations implied that other 
variables and unknown mechanisms (and interactions between them) need to be 
considered to predict the outcome of BoNT-A treatment. Chapter 7 reports on 
the salivary viscoelasticity change after BoNT application. We observed that the 
saliva became sticky in some children after intraglandular botulinum application 
and assumed that sticky saliva may cause swallowing problems due to increased 
protein concentrations and changed salivary viscosity causing more friction. The 
seromucous submandibular glands secrete mucins which coat and protect the 
epithelial tissue of the oral cavity, and give the typical viscoelastic character to 
saliva. In view of the anticholinergic properties of BoNT, it is likely that the watery 
component of saliva will be reduced and that the concentration of mucins will 
increase post-BoNT injection. Therefore, the salivary mucin concentration was 
analyzed before and after BoNT. The submandibular flow was substantially 
reduced with a concomitant increase in mucin concentration within eight weeks 
after BoNT application (from 0.612 up to 1.830 mg/ml). Thickened saliva was 
observed in nine children, and swallowing and chewing were problematic in 
seven children. Two of these children needed treatment with mucolytics because
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of pooling of thickened saliva in the throat. The findings illustrate that in making 
decisions about the use of BoNT, the risk of problems with masticatory and 
swallowing functions due to thickening of saliva after BoNT treatment should be 
taken into account.
It is important to establish the impact of drooling on health and quality of live. The 
last section, chapter 8, shows an international Botulinum Toxin Therapy 
consensus statement for drooling. It assists the clinicians with the assessment, 
intervention and management of children and adults with drooling.
Conclusions and future perspectives
This thesis offers new and relevant information about Botulinum Toxin Therapy 
type A (BoNT-A) for drooling in children with spastic and dyskinetic CP subtypes 
and children with exclusively mental disabilities. It is demonstrated that after 
submandibular BoNT-A injections, the drooling intensity is halved for almost 6 
months in approximately 50% of the children with CP in general. Obviously, the 
CP subtype does not affect the efficacy of submandibular BoNT-A. Although 
submandibular injections of BoNT are effective for drool control, when making 
decisions about the use of BoNT-A, the risk of adverse effects (trauma relation to 
injection, problems with chewing and swallowing as a result of thickening of saliva 
after BoNT-A or because of diffusion of BoNT-A into the surrounding muscular 
tissue) should be taken into account.
Beyond any doubt, the factor quantity of submandibular saliva reduction 
contributes to drooling control, however variables related to handling of secretions 
seem important for the “functional efficacy” of BoNT-A. The discrepancy between 
observed local effect (i.e. decrease of flow) and the clinically reported “functional 
efficacy” (i.e. insufficient drooling control) remains to be proven.1 Although in 
literature head position, movement control, voluntary control over the tongue and 
lips, and mental age2-5 have been reported as contributing to drooling, we found 
no evidence for any influence of these variables on the level of response. When 
grouped together these factors cannot indicate or predict which of the children 
will be responders or non responders with the chosen level of response. Our 
study was the first step to reveal the apparently complicated issue of body 
functions and structures playing a role in drooling and its treatment outcome.
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These observations imply that other variables and unknown mechanisms (and 
interactions between them) need to be considered to predict the outcome of 
BoNT-A treatment. Therefore, we have evaluated the relationship between reflex 
saliva secretion of the parotid gland and observed therapy outcome of 
submandibular BoNT. BoNT-A injections resulted in a substantial direct effect on 
submandibular flow and probably had an indirect effect on the saliva regulation 
mechanisms (peripheral sympathetic inhibition of the reflex salivary secretion; 
central regulation by the hypothalamic circuitries).6,7 There is evidence that the 
Hypothalamic-Pituitary Axis activity is altered in children with neurological 
disabilities8-10, and therapy outcome to submandibular BoNT-A seems to be 
influenced by compensatory strategies of the central circuitries responsible for 
saliva production as well.
Much work still needs to be carried out to improve the management of poor saliva 
control in children with disabilities. In this thesis the used swab method measured 
the quantity of saliva secretion rather than the poor oral motor control, which is 
primarily responsible for drooling. Improved diagnostic and therapeutic 
methodology utilizing real-time imaging modalities, e.g. surface electromyogra­
phy (EMG) of the submental muscle group; ultrasonography or Haste MRI of the 
tongue movements during swallowing, might assist in better defining the clinical 
problem and the outcomes of treatment.
In addition, another point of interest regards the Drooling Quotient. In the study 
described in chapter 3 of this thesis, the VAS and the DQ show a strong relationship 
between the carer’s perception of reduction in their child’s drooling and the 
longitudinal changes in the DQ scores after the saliva-control intervention. 
Clearly, the findings imply that the DQ and VAS enable us to determine the clinical 
effect of BoNT-A for drooling control. Otherwise we recommend the use of the 
swab method for monitoring salivary flow reduction in future intervention studies. 
Finally, given the costs of Botulinum Toxin, the potentially side-effects and the fact 
that anesthesia is needed, it is important to realize what factors might influence 
treatment outcome of Botulinum Toxin injections and formulate strict indications 
for this therapy. In addition, the exact role of behavioral treatment and the surgical 
procedures that are now undertaken for drooling control need to be specified to 
formulate a clinical decision making model for differential indication of treatment 
options across childhood.
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Nederlandse samenvatting en discussie
De optimalisatie van submandibulair Botulinetoxine type A (BoNT-A) behandeling 
om het kwijlen bij kinderen met een Cerebrale Parese (CP) te verminderen is het 
thema van dit proefschrift. CP is de meest voorkomende oorzaak van een 
lichamelijke handicap op de kindertijd. Naar schatting kwijlt 1 op de 3 kinderen 
met een CP pathologisch, waardoor de verdere ontwikkeling ernstig belemmerd 
wordt. Bij de start van het onderzoek wisten we dat met submandibulair BoNT-A 
therapie het kwijlen te verminderen was, maar was het niet duidelijk waarom bij 
een aantal van de kinderen het klinische effect onvoldoende was. Om dit te 
kunnen beantwoorden hebben wij een prospectieve cohort studie uitgevoerd 
waarin 151 Nederlandse kinderen met CP of met uitsluitend een verstandelijke 
beperking meededen.
In hoofdstuk 2 geven we een visie hoe disfunctionerende neuronale netwerken 
van het slikken leiden tot kwijlen. CP is gebruikt als een klinisch model om het 
uitgebreide netwerk te illustreren dat verantwoordelijk is voor de coördinatie van 
de mondmotoriek en de gastro-intestinale functies. Een goede functionele 
afstemming tussen diverse (sub)corticale motorische gebieden, de controlecentra 
in de hersenstam, de hersenzenuwen en de lagere motorneuronen is een 
voorwaarde voor een adequate slikfunctie. Klinische symptomen, zoals orale to- 
nusdysregulatie, onvoldoende controle over de gewilde mondmotoriek (in het 
bijzonder onvolledig lipsluiting, moeite met de tong uitsteken, trage of stijve 
tongbewegingen en verminderde orale suctie), een vertraagde slikinzet of juist 
gesegmenteerd slikken, worden vooral bepaald door de plaats en uitgebreidheid 
van de hersenschade in de corticale gebieden. Pharyngeale slikproblemen, 
d.w.z. juist moeite hebben met automatiseren of plannen van het slikken, zoals 
schonen van de keel of sluiten van de stembanden op het juiste moment, wijzen 
meer op schade in de subcorticale netwerken. Ook het vermogen om de slik met 
de ventilatie te reguleren kan verstoord zijn in CP. Zo kan het inademen op onge­
bruikelijke momenten tijdens het slikken plaatsvinden of kan de slikreflex zelf 
verstoord zijn wat kan wijzen op betrokkenheid van de hersenstam. Uit de review 
komt naar voren dat het brede scala van slik-, ademhaling-, kwijl- en gastro-intes­
tinale problemen begrepen en veroorzaakt worden door (gedeeltelijke) verstoring 
van deze “brain-gut axis”. Het is overduidelijk dat het kwijlen symptomatisch is 
voor neurogene dysfagie en een veel voorkomend neurologisch restverschijnsel
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is. Wij vinden dat ouders/verzorgers en artsen zich in vroeg stadium de grote 
gevolgen van een slikstoornis moeten realiseren.
Hoofdstuk 3 beschrijft een case-control onderzoek waarin onderzocht is of 
hypersalivatie een rol speelt bij het kwijlen van kinderen met CP. Bij 61 gezonde 
schoolkinderen en 100 kwijlende CP kinderen (53 spastische, 42 dyskinetische 
en 5 atactische subtype) werd speeksel verzameld. De conclusie is dat er geen 
sprake is van verhoging van de speekselsecretie bij kwijlende CP kinderen. Wel 
lijkt het kwijlen in de dyskinetische CP intenser, wat mogelijk veroorzaakt wordt 
door hyperkinetische orale bewegingen. Door deze mechanische stimulatie van 
de speekselklieren kan de totale dagelijkse speekselafscheiding (ongeveer 600 
ml) verhoogd zijn met ten minste 200 ml per dag. De bijdrage van de verhoogde 
speekselsecretie van de parotisklieren is tweemaal zo groot als die van de sub- 
mandibulaire klieren. Dit zou kunnen betekenen dat de aanpak van behandeling 
van het kwijlprobleem in deze subgroep mogelijk anders is.
Hoofdstuk 4 beschrijft de effectiviteit en duurzaamheid van submandibulair 
BoNT-A voor kwijlklachten bij 131 kinderen. Follow-up gegevens na 2 en 8 
maanden zijn vergeleken met die van de baseline metingen om het effect en de 
duurzaamheid van de injectie te bepalen. Ongeveer 50% van de patiënten 
reageerden met een significante verlaging van het Drooling Quotient (DQ; 
0-100%): voor de behandeling een gemiddeld DQ van 29% en 2 maanden resp. 8 
maanden na behandeling een gemiddeld DQ van 16% resp. 19%. De Visual 
Analogue Scale (VAS; 0-100mm) toonde een vergelijkbaar patroon (daling van de 
VAS score van 81 naar 53 mm bij 2 maanden; een duidelijke terugkeer naar de 
uitgangswaarde na 8 maanden). Patiënten, die reageerden op een behandeling, 
toonden een terugval na een mediaan van 22 weken. In hoofdstuk 5 onderzoeken 
we de effectiviteit van submandibulair BoNT-A therapie en mechanismen die ten 
grondslag liggen aan de responsactiviteit in 126 kinderen, verdeeld over drie 
groepen: kinderen met spastische of dyskinetische CP, en kinderen met uitsluitend 
een verstandelijke beperking. De bevindingen suggereren dat de effectiviteit van 
submandibulair BoNT-A voor alle groepen gelijk is. In hoofdstuk 6 beschrijven wij 
de eerste poging om de bijdrage van de verschillende lichaamsfuncties en 
structuren (zoals gedefinieerd door de International Classification of Functioning, 
Disability and Health voor kinderen en jeugd (ICF-CY)) op het effect van een 
BONT-A behandeling te bepalen. Uit een literatuurstudie komt naar voren dat 
hoofdpositie, lipsluiting, vrijwillige controle over de tong, gewild bewegen en het
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verstandelijk vermogen bijdragen aan de ernst van het kwijlen. Onderzocht is of 
deze variabelen ook een rol spelen bij het therapieresultaat van BoNT-A. De rol 
van de positie van het hoofd en de lipsluiting op therapierespons lijkt logisch, 
omdat zij beiden door de zwaartekracht beïnvloed worden. Dit geldt ook voor 
gewild bewegen. Immers om efficiënt te kunnen bewegen is een goede 
hoofdpositie en -balans een voorwaarde. Eerdere onderzoeken veronderstelden 
al een correlatie tussen de tongmobiliteit en kwijlen waardoor het aannemelijk lijkt 
dat tongcontrole een belangrijke factor is, die bijdraagt aan de therapie-uitkomst 
van BoNT-A. Ook kan een relatie tussen verstandelijk vermogen en therapie­
resultaat verondersteld worden gezien de mondmotoriek bij toenemende ontwik­
kelingsproblematiek ernstiger verstoord is. Echter na exploratie bleken de vijf 
genomineerde factoren niet bijdragend te zijn aan het therapieresultaat. Dit 
betekent dat nog andere variabelen en onbekende mechanismen voorspellend 
zijn voor het therapieresultaat van BoNT-A. Om de effectiviteit van Botox therapie 
te verbeteren is nader onderzoek naar deze onderliggende variabelen in de 
toekomst noodzakelijk. In hoofdstuk 7 wordt een eerste studie beschreven die 
de verandering van de visco-elasticiteit van speeksel na Botox aannemelijk 
maakt. Na BoNT-A wordt het speeksel bij sommige kinderen dikker van 
consistentie en neemt de wrijving toe, waardoor slikproblemen verklaard zouden 
kunnen worden. De submandibulaire speekselklieren scheiden mucinen uit die 
het epitheelweefsel van de mondholte beschermen en het typische visco- 
elastische aspect aan speeksel geven. Door de anticholinerge eigenschappen 
van BoNT neemt de waterige component van speeksel af, waardoor uiteindelijk 
de concentratie van de mucinen toeneemt. In onze studie hebben wij de mucine- 
concentratie vóór en na submandibulaire BoNT-A injectie geanalyseerd. Het 
blijkt dat binnen acht weken na een BoNT-A injectie de submandibulaire flow 
aanzienlijk vermindert met een gelijktijdige verhoging van de mucineconcentratie 
(gemiddelde concentratie van 0,612 mg/ml toenemend naar 1,830 mg/ml). Het 
speeksel dikte in bij negen kinderen en zeven kinderen hadden slik- en kauw- 
problemen. Twee van deze kinderen moesten worden behandeld met mucolytica, 
omdat het verdikte speeksel in de keel bleef plakken. Deze bevinding toont aan 
dat rekening gehouden moet worden met een verhoogd risico op slik- en 
kauwproblemen als gevolg van indikking van speeksel na BoNT behandeling.
In het laatste deel wordt nogmaals benadrukt rekening te houden met de gevolgen 
van het kwijlen op de gezondheid en de kwaliteit van leven. Hoofdstuk 8
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rapporteert over een internationale Botulinetoxine therapie consensus verklaring 
voor het kwijlen. Mogelijk helpt het de clinici met de beoordeling, interventie en 
de behandeling van het kwijlen bij kinderen en volwassenen.
Conclusies en toekomstperspectieven
Dit proefschrift geeft nieuwe en relevante informatie over Botulinetoxine Therapie 
type A (BoNT-A) om kwijlen bij kinderen met spastische en dyskinetische CP of 
met uitsluitend een verstandelijke beperking te behandelen. Na een eenmalige 
submandibulaire BoNT-A injectie is bij ongeveer 50% van de kinderen de 
intensiteit van het kwijlen gedurende bijna 6 maanden gehalveerd. Het CP 
subtype lijkt de effectiviteit van submandibulair BoNT-A niet te beïnvloeden. 
Hoewel submandibulair BoNT-A een effectieve therapie is om het kwijlen te 
behandelen, moet toch rekening gehouden worden met bijwerkingen (gevolgen 
van een trauma door de injectie, problemen met kauwen en slikken als gevolg 
van indikking van speeksel na BoNT-A of spierzwakte als gevolg van diffusie van 
BoNT-A in het omliggende spierweefsel).
Zonder enige twijfel draagt de speekselreductie bij aan het verminderen van het 
kwijlen (direkt adaptief effect), echter omdat de therapierespons niet altijd even 
goed is, is het belangrijk om te weten welke variabelen nog meer van invloed zijn 
op de werkzaamheid van BoNT-A. Hoewel in de literatuur beschreven is, dat de 
positie van het hoofd, gewilde motoriek, vrijwillige controle over de tong en lippen, 
en de ontwikkelingsleeftijd bijdragen aan kwijlen1-4, vonden we geen bewijs voor 
enige invloed van deze variabelen op de therapierespons van BoNT-A. Echter, 
onze studie was pas de eerste stap om naar de invloed van de verschillende 
I i chaamsfuncties en structuren op het therapieresultaat van BoNT-A te kijken. 
Onze observaties impliceren dat nog andere variabelen en onbekende 
mechanismen (en interacties tussen hen) van invloed zijn op de therapie-uitkomst. 
Daarom hebben we ook de relatie geëvalueerd tussen mogelijke reflexspeeksel- 
secretie van de andere grote speekselklier (parotisklier) en de therapie-uitkomst 
van submandibulair BoNT-A. BoNT-A injecties hebben een indirect effect op de 
speekselregulatie via perifere sympathische reflexinhibitie of door centrale 
regulering via de hypothalamus.5,6 We zien inderdaad dat na BoNT-A behandeling 
de speekselsecretie van de parotisklier afneemt en mogelijk gebeurt dit door
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perifere sympathische inhibitie. Echter bij sommige kinderen wordt de verminderde 
submandibulaire speekselflow maar (deels) gecompenseerd door enige stijging 
van de parotisflow. De hypothese is dat dit waarschijnlijk centraal gereguleerd 
wordt, waarschijnlijk door de hypothalamus. Wij denken dus dat therapie-effect 
van submandibulair BoNT-A ook beïnvloed kan worden door gedeeltelijke 
toename van de speekselsecretie van de parotisklier. Het is duidelijk dat nog veel 
werk verzet moet worden om de behandeling van kwijlen bij kinderen met een 
handicap te optimaliseren. De in dit proefschrift gebruikte swabmethode meet de 
speekselsecretie in plaats van de slechte orale motorische controle wat uiteindelijk 
primair verantwoordelijk is voor het kwijlen. Wij verwachten dat verbeterde 
diagnostische methoden, zoals het gebruik van real-time beeldvorming, 
bijvoorbeeld oppervlakte elektromyografisch (EMG) onderzoek van de submentale 
spiergroep, Haste MRI of echografie van de tong tijdens het slikken, kunnen helpen 
bij het beter in kaart brengen van het klinische probleem of te wel de aard en ernst 
van de slikstoornis. Wij denken dat hierdoor de resultaten van de behandeling 
weleens zouden kunnen verbeteren.
Voorts willen we hier een opmerking maken over het gebruik van het Drooling 
Quotient. De VAS en DQ, beschreven in hoofdstuk 3 van dit proefschrift, tonen 
een sterke relatie tussen de perceptie van de verzorger over de vermindering van 
het kwijlen en de longitudinale veranderingen in de DQ scores na de BoNT 
interventie. De bevindingen impliceren dat de DQ en VAS ons in staat stellen om 
in de klinische praktijk het effect van BoNT-A therapie adequaat te vergelijken. 
Daarentegen moet de swabmethode voortaan alleen nog gebruikt worden in 
interventiestudies om de speekselreductie te monitoren.
Tot slot, gelet op de kosten van Botulinetoxine behandeling, de bijwerkingen en 
het feit dat steeds anesthesie nodig is, is het onontbeerlijk om inzicht te hebben 
in factoren die mede van invloed zijn op de effectiviteit van de BoNT-A behandeling. 
Dan pas wordt het mogelijk om strikte indicaties voor deze therapie te formuleren. 
Bovendien moet de precieze rol van de gedragstherapeutische behandeling en 
de chirurgische ingrepen, die nu worden uitgevoerd om het kwijlen te behandelen, 
gespecificeerd worden, zodat uiteindelijk een klinisch besluitvormingsmodel 
voor gedifferentieerde behandelopties voor de kindertijd geformuleerd kunnen 
worden.
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